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Progression of chronic renal failure
Like most other organs in the human body, the kidney is prone to a gradual,
albeit small, loss in function over the decades. This physiological phenomenon is
clearly demonstrated by the gradual fall in glomerular filtration rate with increasing
age [1]. Fortunately, this small decrease in renal function is usually of no clinical
significance. However, in patients with a renal disorder, the rate of renal function loss
can be significantly enhanced, even if the primary insult or underlying disease activity
has already abated. This will result in several metabolic disturbances, and eventually,
for many patients, in  end-stage renal failure. The course of renal function loss can
be described  as the reciprocal of serum creatinine level against time, resulting in a
straight line in the majority of patients [2]. Interestingly, the rate of renal function
loss shows a remarkable interindividual variability between patients, even if they have
a similar underlying disorder [2]. This suggests that progression of renal function loss
appears to be largely independent of the type of underlying renal disease, but that
other factors are involved. 
It is obvious that the prevention of progressive renal failure is of paramount
importance to the patient and also to reduce the high costs for the treatment of
these patients. Unfortunately, we are still not capable to prevent the onset of many
types of renal diseases. However, numerous observations have made it clear that
progression of renal function loss is largely dependent upon secondary factors [3,4].
Systemic and glomerular hypertension, proteinuria and hyperlipidemia are assumed
to be the most common mediators in the final common pathway of progressive renal
damage [5].  These common risk factors are often present simultaneously and
mutual interaction of these risk factors appears to accelerate progressive renal
damage.
Genetic factors in renal disease
As already noted, the rate of long-term renal function loss displays a
considerable variability between individuals, even between those who have the same
type of renal disease [2]. However, within one individual, the rate of renal function
loss remains fairly constant. For this phenomenon, genetic determinants of
progression rate may provide an additional explanation. The major impact of ethnic
background on the risk of progressive renal function loss in renal disease supports
this role for genetic factors [6]. Familial clustering of endstage renal disease provides
an additional clue indicating the importance of genetic factors [7]. Before the area of




chronic renal disease had been considered primarily in the context of single-gene
diseases with Mendelian inheritance, such as Alport syndrome or polycystic kidney
disease. Animal data have provided  evidence for a role of genetic determinants in
the susceptibility to develop progressive renal function loss and glomerulosclerosis
[8]. In humans, familial clustering of diabetic nephropathy [9], and the presence of
distinct HLA patterns  in association with membranous glomerulopathy [10], IgA
nephropathy [11] and focal segmental glomerulosclerosis [12] all suggest that
genetic factors are involved. This can either be a susceptibility to acquire certain
disease or a disease course-modifying one. The impact of genetic factors is likely to
be complex and multifactorial in contrast to association with single-gene mutations.
Thus, gene-gene and/or gene-environment interactions are  likely to play a role. 
Genetic polymorphisms
Recent advancements in molecular genetic techniques have provided new
insights in the role of genetic variability in renal disorders with respect to the
likelihood to develop renal disease, the course of renal disease and the benefit of
renoprotective therapy. Much effort has been put in discerning the role of genetic
polymorphisms. Mutations in the human genome occur frequently. Their
consequences can be variable. A first possibility is that the affected offspring is
spontaneously aborted or becomes burdened with clear clinical signs of disease. By
this mechanism the mutation cannot easily be passed on to a next generation. This is
called selection pressure. However, if the mutation does not have deleterious
consequences, offspring can survive and appear relatively healthy. In some cases
subjects develop disease but also have advantages, for example patients with sickle
cell anaemia who are less prone to acquire malaria. In case of no clear disease, the
mutation can readily be transmitted from generation to generation, disseminating into
a gene pool of a large population, causing no or only minor inconvenience. Thus,
selection pressure is absent. This phenomenon of having two or more allele variants
is called polymorphism. In general, a genetic locus is considered polymorphic if the
rarest allele has a frequency of >1% [13,14]. This results in a heterozygote frequency
of at least 2%. At such a frequency, a mutation cannot be maintained by recurrent
mutation alone. Such DNA polymorphisms are now known to exist for the major, if
not all, human genes. The best known examples are the ABO- and rhesus bloodtype
systems and the HLA-system. There are two different kinds of polymorphisms. First,
the restriction length polymorphisms. By variation in the presence or abscence of
certain nucleotide sequences, DNA-restriction enzymes recognize sequences resulting
in DNA fragments of different lenghts. Secondly, there can be a variable number of
nucleotide sequence repeats. These short or long “tandems” can be repeated up to
several hundred times. Polymorphisms can be present on a coding DNA-sequence
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(exon). In this case the polymorphism results in the production of an altered protein.
However, the polymorphism can also be present on a non-coding DNA-sequence
(intron). This does not result in altered protein production but nevertheless can have
functional consequences. For most of these intron polymorphisms it is not clear
whether there is an interaction between certain exons or whether the introns merely
are a marker of disease because they are closely linked to a certain exon.
Genetic polymorphisms as a new clue for disease susceptibility
It is hypothesized that the complex interaction between multiple
environmental factors and inherited genetic polymorphisms could result in the
susceptibility to certain diseases or to modify the course of diseases, by having each
a small, but additive impact.  It recently was suggested that genetic polymorphisms
can affect the susceptibility to fairly common diseases as hypertension, diabetes
mellitus, osteoporosis and Alzheimer disease [13]. However, the path to dissect the
impact of genetic polymorphisms is not an easy one. As each  polymorphism appears
to have only a small impact on the phenotype, identification of such susceptibility
genes is far more difficult compared to the identification of major chromosomal
abnormalities or single gene mutations. This is because even the presence of several
susceptibility alleles at multiple loci does not necessarily lead to overt clinical
symptoms, postulated to be caused by a subtle difference in exposure to
environmental influences [14].  
Genetic polymorphisms and renal disease
Careful characterization of clinical phenotypes and detection of genetic
markers for the susceptibility to acquire renal diseases or modify its course, has been
difficult and cumbersome. However, several genetic variabilities have been linked to
renal disease. Gene variation of the complement system has been identified with the
occurence of IgA nephropathy [15,16]. Also, significant variation in the major
histocompatibility complex was found to be relevant to renal disease. HLA-DR2 and
HLA-3 were associated with membranous nephropathy [17], and DR-1 and HLA-B35
were associated with IgA nephropathy with a poorer prognosis in patients with HLA-
B35 [11]. A polymorphism of a transporter protein, associated with antigen
processing (TAP1 variation), has been associated with membranous glomerulopathy
as well. [18]. The severity of many inflammatory disorders has been linked with
polymorphisms of several proinflammatory molecules as TNF-α and TNF-β and




associated with altered cytokine production in patients with IgA nephropathy and
membranous glomerulopathy [13]. 
Angiotensin-converting enzyme insertion/deletion (I/D) polymorphism
The renin-angiotensin aldosterone system (RAAS) has a key role in both
cardiovascular and renal  pathophysiology [21, 22]. Angiotensin II (angII), the most
important biological active product, is synthesized via a pathway that involves several
precursor peptides and enzymes, some of them regulated by separate genes. The
main known action of angII is its potency to constrict vascular smooth muscle cells
and to stimulate fluid and sodium retention, by directly acting on tubular cells and
through stimulating aldosterone release. However, more recently other potential
actions of angII have been elucidated. Several studies have revealed that angII in
vitro promotes vascular smooth muscle, glomerular mesangial and renal tubular cell
growth [3, 21, 22].  AngII  also appears to be involved in the accumulation of
collagen by both activating collagen synthesis and inhibition of its degradation [13].
Interference in the fibrinolytic process, by stimulating plasminogen activator inhibitor
(PAI-1) is another finding that emphasises the importance of angII in cardiovascular
and renal pathophysiology [23]. Therefore, it is clear that genetic polymorphisms of
the RAAS have gained interest in the search for genetic factors that might influence
the progression of chronic renal failure and the response to treatment to
renoprotective regimens. 
Angiotensin I converting enzyme (ACE) is a zinc metallopeptidase widely
distributed on the surface of endothelial and epithelial cells. By stimulation of renin,
angiotensinogen is converted to angiotensin I. ACE then converts angiotensin I to
angiotensin II, the main active product of the RAAS. The human ACE gene is located
on chromosome 17q23 and includes 26 exons. The coding sequence codes for a 1306
amino-acid protein, including a signal peptide. The geneproduct, ACE, is composed of
2 homologous domains with 2 active sites. In 1990, the group of Rigat et al.
published an important report that was an impuls to further studies on gene
polymorphisms of the RAAS [24]. They found a polymorphism involving  the presence
(insertion) or absence (deletion) of a 287-basepair sequence of DNA in intron 16 of
the gene coding for ACE (Figure 1). Interestingly, in Caucasian subjects, the mean
ACE activity in DD genotype individuals was about twice that found in II genotype
individuals [24]. Subjects with ID genotype had intermediate levels indicating co-
dominancy, that is, the effects of both alleles are detectable in heterozygotes. It was
hypothesized that the  higher ACE activity could result in an increased angI to angII
conversion. Considering the importance of angII in cardiovascular and renal
pathophysiology, it is not surprising that many studies have tried to find an
association between the prevalence and course of cardiovascular and renal disease
and ACE I/D polymorpism. 












Schematic presentation of the insertion (I) and deletion (D) alleles of the human
angiotensin I converting enzyme gene at the I/D polymorphic locus at intron 16. A and B
represent flanking oligonucleotides. By polymerase chain reaction (PCR) oligonucleotide
flanking primers A and B result in a 490 basepair nucleotide in the I-allele and a 190
basepair nucleotide in the D-allele. Using only A en B flanking primers, the insertion allele
can be missed in heterozygotes, thus resulting in mistyping as DD genotype. For this
reason an insertion specific primer (C) is used. PCR of C and B primer yields the
amplification of the 335 bp product in II and ID subjects, but not in DD subjects, thereby
discriminating between ID and DD genotype with certainty. 
         A B
A B
nking primer PCR Insertion specific PCR
II         ID       DD
 allele
335 bp -




From genotype to phenotype
In spite of the great effort that has been put in the many association studies
that have been published, the role of the ACE I/D gene polymorphism has not
become much clearer. This is mainly due to the fact that association studies can only
show a statistical correlation (often relatively weak) between polymorphisms and  an
increased risk to develop a disease or to have progressive organ damage. However,
from a pathogenetic point of view, this does not prove a causal relationship. This is
well illustrated by studying how a polymorphic fragment of DNA (the genotype) is
related to a gene allele that causes disease (phenotype). If the polymorphism and the
disease allele are physically close to each other, both are “linked” and inherited
according to Mendelian law. However, the distance between these DNA fragments is
not always that close. This results in a “linkage disequilibrium”, in which the
polymorphism does occur more often together with a certain phenotype than can be
expected according to the gene frequencies of a population, but linkage is not always
present. Because of the many contradictory association studies on ACE I/D
polymorphism and cardiovascular and renal disease it may be likely that the
insertion/deletion allele is not that close to the real disease inducing or disease
modifying alleles. It is therefore clear that association studies are not likely to answer
all our questions. Different studies have also investigated populations of different
ethnic origin. This makes comparison between association studies even more difficult.
In conlusion, it is clear that we are in great need of more basic physiological
studies that investigate the consequences of ACE I/D polymorphism in renal
pathophysiology. Only then we can understand the impact of ACE I/D polymorphism
on the onset and course of renal disease and eventually develop treatment strategies
specifically adapted to certain genetic risk profile. Finally, we should also taken into
account the impact of certain exogenous factors involved in gene-environment
interactions as many exogenous factors have great impact on the development and
course of disease. Such gene-environment interactions should certainly need more
attention in future studies. In the present thesis we will address these questions and
also provide an overview on the vast amount of data that have been collected during
the past years.
OUTLINE OF THIS THESIS
Chapter 2
Studies on ACE I/D polymorphism have provided a bulk of data.
Unfortunately, rather than clarifying the role of the ACE I/D polymorphism, it has
become increasingly difficult to interpret these studies. Chapter 2 will give an
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overview on what is known on the role of ACE I/D polymorphism concerning the
incidence of renal disease. We will discuss the  role in progression of chronic renal
failure, the impact on therapy response, physiological studies and the potential
pitfalls in interpreting this data. Finally, we will discuss putative mechanisms for the
association between the DD genotype and progression of renal disease and suggest
directions for future research.
Chapter 3
In 1996, van Essen et al. from our department, published data on the impact
of ACE I/D polymorphism on the rate of renal function loss during protocollized
treatment with either enalapril or atenolol, in a population with chronic non-diabetic
renal disease [25]. In subjects with ACE DD genotype, the rate of renal function loss
was significantly faster as compared to subjects with ID  and II genotype,
irrespective of the efficacy of reduction of proteinuria and blood pressure [25]. These
results suggested a therapy failure in DD genotype subjects. However, pre-
intervention rate of renal function decline, for each genotype group separately, were
not available at that time. This chapter will show the remarkable results of analyzing
the pre-intervention rate of renal function loss in both the randomized
enalpril/atenolol prevention trial and also the post-hoc analysis on ACE polymorphism
[26, 25]. We will also discuss the importance of the pre-intervention rate of renal
function loss on the benefit of renoprotective therapy in general. Although not
specific to studies on genetic polymorphisms, these data can be helpful in the
interpretation of studies on ACE I/D polymorphism, since many have a post-hoc
character. 
Chapter 4
Although therapy response to ACE-inhibition was demonstrated in chapter 3,
the renal outcome in the population described in chapter 3, in terms of progression in
renal function, is still worse in DD genotype. One hypothesis was that this finding
could be explained by an impaired short-term therapy response in DD individuals.
This appeared of special interest since Apperloo et al. had previously demonstrated
that short-term antiproteinuric and hemodynamic response could predict the
response in terms of long-term renoprotection in proteinuric renal patients [27]. To
test this hypothesis, chapter 4 will discuss a study in 61 proteinuric patients in whom






Whereas the results from the study presented in chapter 4 provide no data to
support a role of ACE I/D polymorphism in the short-term therapy response to ACE-
inhibition, several other studies showed different results with either a positive or
negative association between ACE DD genotype and a good antiproteinuric and
antihypertensive response to ACE-inhibition. The study presented in chapter 5 was
inspired by the ASN meeting in New Orleans, USA 1996, were we met Austrian
investigators that performed a  study quite similar to ours but with therapy resistance
to ACE-inhibition in DD genotype [28]. A difference in sodium intake between the two
Caucasian population resulted in the hypothesis that ACE genotype might influence
sodium dependency to the short-term response to ACE-inhibition. This collaborative
study is discussed in chapter 5. 
Chapter 6
Many studies have studied the role of ACE I/D polymorphism in renal disease.
All based their hypothetical association on the assumption that a higher plasma ACE
level will result in an increased conversion from ang I to angII. Data on the response
to angI however, are both scarce and conflicting [29-31]. We therefore investigated
the effect of both angI and angII infusion on systemic and renal hemodynamics and
also on hormonal responses to angI. In this chapter, we especially try to discern the
role of sodium intake as exogenous RAAS modifier and example of gene-environment
interaction.  
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In recent years a vast amount of data has been published on the association
between the insertion/deletion (I/D) polymorphism of the gene coding for
angiotensin- converting enzyme and renal disease. It has become clear that the
polymorphism does not affect the prevalence of renal disease. However, data on the
association with progression of renal disease and therapy response are still
contradictory. Moreover, sufficient data on the physiological significance of this
polymorphism are still lacking.  This contribution provides an overview of the
available studies and the potential pitfalls in interpreting the data. We also discuss
the putative mechanisms for the association between the DD genotype and
progression of renal disease and suggest directions for the future that might be
employed to further clarify the role in renal pathophysiology.     
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INTRODUCTION
Recent advances in molecular genetic techniques have provided great
potential for elucidating the role of genetic factors in common, multifactorial disorders
such as cardiovascular and renal diseases. In nephrology the focus on genetic factors
was largely limited until recently to single-gene disorders of Mendelian inheritance
such as polycystic kidney disease. However, familial clustering of diabetic
nephropathy [1] and the association of specific renal disorders [2-4] with distinct HLA
patterns suggests a more extensive role of genetic factors. Furthermore, in chronic
renal disease the individual rate of long-term renal function loss is often fairly
constant [5] with a wide interindividual variation even among patients with the same
disorder, suggesting that individual factors - genetic or otherwise - are relevant to the
course of renal disease. 
Interest in the role of genetic factors in renal disease received  new impetus
with the finding of an insertion/deletion (I/D) polymorphism of the angiotensin-
converting enzyme (ACE) gene [6] with overrepresentation of the D allele in patients
with myocardial infarction [7]. While subsequent studies had provided conflicting
results, recent meta-analyses support an association of the D allele with a modest
elevation in cardiovascular risk [8,9]. As the DD genotype is associated with elevated
ACE levels [6], it has been suggested that increased formation of angiotensin (Ang) II
is involved. As AngII plays an important role in renal pathophysiology, these findings
elicited an upsurge of studies on the association of the  ACE I/D genotype (and other
polymorphisms of the renin-angiotensin aldosterone system (RAAS)) and renal
disease, giving rise to sometimes conflicting results. 
Methodological limitations of the available studies, such as insufficient sample
size, ethnic heterogeneity, inaccurate definition of the renal phenotype, and possible
publication bias have been claimed to be responsible for hampering interpretation of
the conflicting data. In addition, features specific to renal disease can be expected to
cause selection bias as outlined in more detail below [10-12]. 
Genetic factors may affect the renal disease phenotype in several ways: the
susceptibility for acquiring renal disease, the natural course of the disease and the
response to therapy. Distinguishing between these possible mechanisms is necessary
to understand the role of genetic factors in renal disease, and, even more
importantly, the implications for prevention and therapy. In this contribution, we
present  an overview of the current state of knowledge on the ACE (I/D)





ACE is a glycoprotein present in almost all mammalian tissue and body fluids.
Its molecular biology and genetics have been reviewed extensively [13], and are only
briefly outlined here. ACE occurs in a circulating form and as an ectoenzyme bound to
cell membranes [14,15] The conversion of AngI to Ang II, and the inactivation of
bradykinin are considered its main functions but ACE cleaves many other
oligopeptides as well. The stability of individual plasma ACE levels, combined with
marked interindividual differences [16,17.] and the familiar clustering of plasma ACE
levels suggests its regulation to be under major gene control [18,19.]. This led to
genetic studies on human endothelial ACE, that have identified an I/D polymorphism
on the ACE locus on chromosome 17 of a 287- basepair fragment on intron 16 [6].
The plasma ACE level is some 60% higher in DD homozygotes than in II
homozygotes with intermediate values in heterozygotes. In human cardiac tissue [20]
and in T-lymphocytes [21], ACE levels are also highest in DD homozygotes.
Immunostaining in kidneys of healthy DD homozygotes reveals more ACE-positive
glomeruli than in kidneys of II or ID subjects, with possibly a slight increase in
proximal tubular immunostaining as well [22]. In seminal fluid on the other hand,
where ACE occurs in its germinal form, ACE levels are not affected by ACE genotype
[23.], suggesting interaction of local with genetic factors in the regulation of ACE
expression. The functional properties of the enzyme appear to be independent of
genotype [24].
The mechanism accounting for the elevated ACE levels in DD homozygotes is
unknown. Because the polymorphism is located on an intron, it may simply be in
linkage disequilibrium with a functional variant of the ACE gene or  suppress
transcription. The increase in cellular ACE suggests effects at the transcriptional or
translational level rather than increased cleavage from membrane-bound enzyme.
Segregation-linkage analysis has identified additional ACE gene polymorphisms,
suggesting several quantitative trait loci. These may include the I/D polymorphism,
the newly identified 4656(C/T)2/3 ACE gene polymorphism, but effects of additional
loci are likely [25].
In heterozygotes the I allele may be difficult to detect, thus overestimating
DD frequency [26-28]. This pitfall may have affected the results from early studies. It
can be circumvented by adding dimethylsulphoxide (DMSO) or repeating the PCR
with intron- specific primers [29].
POPULATION ASPECTS
The I/D polymorphism is present in all populations studied thus far, with
marked ethnic differences [30]. In healthy Caucasian populations the D allele
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frequency ranges between 0.50 and 0.63. In subjects of African descent D allele
frequency is in the same range or slightly higher [31,32]. In healthy Japanese and
Chinese the D allele frequency is lower, ranging from 0.27 to 0.40 [33]. The lowest
values have been reported among the Yanomami of South America (0.15) and among
Samoans (0.09) [30]. Ethnic factors also affect the genotype-phenotype relationship,
as shown by the weaker correlation between ACE I/D genotype and circulating ACE
levels in subjects of African descent [31,34]. 
The ACE genotype distribution is in accord with the Hardy-Weinberg
equilibrium in healthy populations irrespective of ethnic origin [30]. This suggests
either the absence of negative selection pressure, or concomitant positive selection
pressure in the normal population. Evidence that the DD genotype does not exert
negative selection pressure has been provided for instance, by the Copenhagen City
Heart Study [35] and by the intriguing finding of an overrepresentation of the DD
genotype among centenarians [36].
ACE GENE POLYMORPHISM AND RAAS PHENOTYPE 
ACE plays an important role in the RAAS cascade (Figure 1) by converting
AngI to AngII. This is effected not only by plasma ACE but mainly by ACE bound to
the surface of the vascular endothelium [13]. AngII is a potent vasoconstrictor of the
systemic and the renal vascular bed. These effects are mediated by the AngII type 1
(AT1) receptor. Moreover, AngII modulates tissue growth and repair in the kidney and
in the vasculature [37-40] by effects on both the AT1 receptor [41] and the AT2
receptor [42,43]. Each of these hemodynamic effects of AngII, i.e., increased
systemic and glomerular blood pressure, and its effects on tissue growth, such as
promotion of mesangial hypertrophy [36] and interstitial fibrosis, are thought to be
involved in progressive renal function loss [37,39,41,44]. 
Several studies have investigated whether the elevated ACE levels in DD
heterozygotes have functional consequences for the RAAS phenotype. Plasma levels
of RAAS components, i.e. renin, AngII and aldosterone are reported to be similar in
various genotypes [45]. On the other hand, several investigators have provided
evidence of enhanced conversion of AngI to AngII in the DD genotype under
experimental conditions. An increased vasoconstrictor response to AngI was found in
isolated human arteries from DD homozygotes, demonstrating increased vascular
conversion of AngI [46] This was confirmed by a study in a human forearm model
[47]. Ueda et al. found an increased pressor response to exogenous angI in healthy
DD homozygotes, associated with an enhanced rise in systemic AngII levels,
supporting increased in vivo conversion of AngI [48]. Lachurie et al, on the other
hand, found no difference between genotypes in response to exogenous AngI during




RAAS-activity [45]. The relevance of background RAAS activity is supported by the
finding of a more pronounced pressor response to AngI in healthy DD homozygotes
during liberal sodium intake , but not during low sodium intake [49].
Whether such an increased conversion of pharmacological doses of AngI has
an impact on (patho-)physiological processes is still unknown, but these data are
consistent with increased AngII generation in DD patients in conditions of RAAS-
activation, such as occurs in several cardiac and renal disorders.
Regarding the other main function of ACE, the inactivation of bradykinin, even fewer
data are available. Data on responses to exogenous bradykinin in the various ACE
genotype  groups are at present conflicting [50,51].
Figure 1. Schematic representation of the role of angiotensin-converting enzyme (ACE) in the renin-
angiotensin-aldosterone cascade and in bradykinin cleavage. The encircled arrows indicate
the alterations in phenotype thus far demonstrated in DD homozygotes: elevated ACE,










AT1  systemic vasoconstriction
AT1  renal vasoconstriction
AT1
AT2 Tissue growth and repair
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ACE GENE POLYMORPHISM AND THE SUSCEPTIBILITY TO RENAL DISEASE
If ACE polymorphism affects the susceptibility to acquiring specific renal
disorders, overrepresentation of a particular genotype under these conditions would
be expected. However, many renal conditions can have an insidious, asymptomatic
onset and go undiagnosed altogether unless the disease follows a progressive course.
By the resulting selection bias, association studies in established renal disease may
not merely reflect susceptibility, but also a progressive course.   
Most of the data so far available are on diabetic nephropathy, which allows
the role of ACE genotype to be assessed by meta-analysis. Fujisawa et al. found an
association between nephropathy and the D allele with an odds ratio of 1.32 in 4773
patients from 18 studies of heterogeneous populations in Europe and Japan,
including micro- and macro-albuminuric insulin-dependent diabetes mellitus (IDDM)
as well as non-insulin dependent diabetes mellitus (NIDDM) [52]. Two subsequent
meta-analyses, however, have differentiated between IDDM and NIDDM on the basis
of ethnicity and have confirmed  this association only in Japanese NIDDM patients.
Tarnow found a pooled odds ratio of 1.41 (95% CI 0.93-2.12) in five studies of
Japanese NIDDM patients (n=738), but no association in 11 studies of IDDM patients
(n=1371) and in five studies of Caucasian NIDDM patients (n=730) [53]. Kunz et al.
(19 studies, n=5336) found no association in IDDM or NIDDM among Caucasians, but
a pooled odds ratio of 1.88 (1.42-2.85) in Japanese patienst with NIDDM [10]. 
The risk of developing diabetic nephropathy is presumably multifactorial.
Barnas et al, in well-documented single-center population, found an interaction
between the D allele, blood pressure and long-term glycemic control in the risk for
nephropathy in IDDM [54]. Although this has not been found uniformly [55], this
study is of interest as it illustrates an important notion in the study of multifactorial
disease, that is, the relevance of considering multiple risk factors to assess both their
respective specific importance and the role of their interaction. A possible mechanism
for the interaction between ACE genotype and glycemia is provided by Marre, who
found that the II genotype protects against glycemia-induced hyperfiltration in IDDM
[56].
Studies From Europe and Japan consistently show the allele frequency and
genotype distribution to be normal in IgA nephropathy [57-60]. Also, the recurrence
of IgA nephropathy does not depend on genotype in renal transplants [61]. A normal
genotype distribution has been reported in patients with membranous
glomerulopathy [62]. A Korean study reported a normal genotype distribution in
minimal change nephropathy, but an overrepresentation of the DD genotype in focal
segmental glomerulosclerosis [63]. However, focal segmental glomerulosclerosis is
thought in most cases, to be the final outcome of a progressive course of various
renal disorders, rather than a primary renal condition [64]. The latter association may
therefore, reflect a progressive course rather than the susceptibility to acquiring renal




hypertensive renal vascular damage, as manifested in biopsy-confirmed hypertensive
nephrosclerosis [65], hypertension-associated albuminuria [66,67], and overt
renovascular disease [68].
Taken together, the evidence does not support an important role for the ACE
genotype in the susceptibility to acquire primary glomerular or tubulo-interstitial
disease. On the other hand, the D allele appears to be associated with conditions in
which renal micro- or macro-vascular damage plays a major role in pathophysiology.
This view is in accord with the large meta-analysis by Staessen et al. (145 studies;
n=49959) on hypertension, cardiovascular and renal disease, that concludes that the
D allele is associated with macro- and micro-vascular complications in both
cardiovascular and renal disease [9]. The data on renal disease secondary to NIDDM
are difficult to interpret. The NIDDM population is likely to be prone to selection bias.
Moreover, histological confirmation of the renal diagnosis is lacking in most patients,
whereas a considerable proportion of biopsied NIDDM patients have renal lesions
atypical for diabetic glomerulopathy [69,70].   
ACE GENE POLYMORPHISM AND THE PROGRESSION OF RENAL DISEASE 
Conclusive evidence of a role of ACE polymorphism in the progression of renal
function loss would require prospective studies with patients selected by genotype
and followed from the time of onset of renal disease. However, such studies are
lacking so far. Available studies take one of two main approaches. The first analyzes
allele frequency in patients with end-stage renal failure (i.e. haemodialysis patients or
transplant recipients), or compares patients defined as "progressors"  to healthy
controls or "non-progressing" renal patients. The second approach compares the rate
of renal function loss (serum creatinine over time or glomerular filtration) in patients
with various genotypes. 
An increased frequency of the D allele has been reported in mixed
populations of haemodialysis patients [71], in renal transplant recipients [72] and in
haemodialysed patients with NIDDM [73] or IDDM diabetes [74], suggesting an
association between the D allele and the progression of renal function loss. This
finding, however, has not been confirmed in other studies in Caucasian hemodialysis
patients with renal failure of mixed origin [75], IgA nephropathy [57], membranous
glomerulopathy [62] and in Japanese haemodialysis patients [76]. 
Table 1 presents an overview of studies providing longitudinal renal follow-up. The
majority of these studies have found the D allele to be associated with an increased
risk of long-term renal function loss or a worse renal survival, such as in  IgA
nephropathy [58-60,77], IDDM [78], NIDDM [11], adult polycystic kidney disease
[79] and populations with renal conditions of diverse origin [71,80,81]. Other studies,
however, in patients with IgA nephropathy [82], adult polycystic kidney 
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retrospective 168 renal survival worse in DD Yoshida (11)
IgA retrospective 100 creatinine/time worse in DD Harden (58)
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observational 35 GFR decline worse in DD Parving (78)
APKD retrospective 189 renal survival worse in DD Baboolal (79)
NDRD,mixed prospective,
post-hoc
81 GFR decline worse in DD van Essen (80)
childhood FGS retrospective 47 mixed better prognosis II Frischberg (81)
NDRD, mixed retrospective 116 change creatinine no effect genotype Burg (84)
NDRD, mixed prospective,
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226 GFR decline no effect genotype Zocalli (85)
transplant
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retrospective 269 renal survival no effect genotype Beige (86)
transplant
recipients
retrospective 367 renal survival worse in DD Broekroelofs (87)














NDRD = non-diabetic renal disease
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disease [83] and diverse glomerular disorders [84,85], have yielded negative results.  
How can this heterogeneous body of data be interpreted ? As noted above,
methodological limitations inherent to the study of complex multifactorial diseases by
association studies complicate interpretation of the data [10,12]. These include
inadequate sample size, heterogeneity in genetic (ethnic) background and
environmental factors within the studied populations, and inaccurate definition of the
renal disease phenotype. Selection bias may also be involved, not only because
patients are included for reasons other than their ACE genotype - inherent to all
retrospective studies - but also because ACE genotype may affect mortality by a
concomitant effect on cardiovascular risk. Moreover, chronic renal disease as such is
associated with increased mortality, which could elicit additional selection bias by
underrepresentation of alleles promoting renal function loss in cross-sectional studies.
Evidence of such a selection bias has been provided by Yoshida et al. who report a
particularly high mortality among NIDDM patients with the DD genotype after
initiation of haemodialysis [11]. This is likely to impair the sensitivity of studies in
end-stage renal failure populations to detect an effect of the D-allele as a promoter of
renal function loss [12]. Finally, there may be a publication bias, as suggested by the
smaller sample size in studies with positive findings than in those with negative
findings, but its overall effect is hard to estimate. All these limitations must be
considered in interpreting the above studies. 
As the D allele is reported to be either indifferent, or associated with a worse
renal prognosis, the evidence seems to favour a role for the D allele in the
progression of renal function loss, albeit not in all populations and not under all
circumstances. Thus, to understand its significance for the multifactorial process of
renal function loss, two issues come into focus. First, its relative impact compared to
other renal risk factors, as this allows an estimate of its overall impact in renal
disease.  Second, its possible interactions with other genetic or environmental renal
risk factors, as this could identify the circumstances that allow the D allele to exert a
negative effect on renal prognosis. 
Several clues  to answering these questions can be derived from the above-
cited studies. Hunley et al reported that the risk associated with the D allele is more
apparent in patients without proteinuria or hypertension. This suggests that the
presence of other renal risk factors overrules an effect of the D allele, indicating that
it is a risk factor of only modest potency as compared to proteinuria and
hypertension. It also implies that the presence of other risk factors must be
considered in evaluating its contribution to the overall renal risk in a given population.
This is supported by data from renal transplant recipients. Renal graft  survival was
not different for recipients with different genotypes [86,87]. However, when the
presence of other renal risk factors are included by multivariate analysis, the recipient
D allele remains an independent risk factor for graft loss [87]. 
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Several studies support an interaction with the angiotensinogen (AGT) M235T
polymorphism. Pei et al reported that, when tested separately, AGT genotype but not
ACE genotype, is associated with progressive renal function loss in IgA nephropathy
[88]. Patients with the AGT T-allele show a rapid progression rate irrespective of ACE
genotype, while AGT MM homozygotes have rapid progression only when the DD
genotype is concomitantly present. In line with these findings, the severity of renal
involvement has been found to be increased from the AGT MM to TT genotype in
diabetic subjects harbouring the D allele [89]. In adult polycystic kidney disease, on
the other hand, no such interaction has been confirmed [79]. Thus, the role of these
other RAAS polymorphisms require further study before conclusions can be drawn.
ACE GENE POLYMORPHISM AND THE RESPONSE TO THERAPY
The association between ACE levels and ACE genotype led to the view that
ACE genotype might affect the response to ACE-inhibition. ACE inhibitors play a
prominent role in the management of renal patients [90] as they lower blood
pressure and the severity of proteinuria [91], and retard the rate of long-term loss of
renal function in both diabetic and non-diabetic nephropathy [92-94.]. Response to
therapy however, varies considerably between patients, both in the short-term and in
the long-term [95]. Interestingly, an effective short-term response of proteinuria and
renal hemodynamics predicts the efficacy of long term renoprotection. Therefore,
antiproteinuric efficacy is thought to be the principal intermediate parameter for long-
term renoprotection [95,96]. 
The mechanism underlying individual differences in response to ACE-inhibition
remains unclear and may well involve genetic factors. It has been suggested that the
higher ACE levels would make DD homozygotes particularly susceptible to the
beneficial effects of ACE-inhibition. On the other hand, blockade of AngII generation 
during infusion of exogenous AngI by a single dose of an ACE inhibitor is reported to
be of shorter duration in DD homozygotes than in those with ID/II [97]. The various
clinical studies on the role of ACE genotype in the response to therapy among renal
patients reach conflicting results. Table 2 summarizes studies reporting on the
antiproteinuric efficacy of ACE-inhibition. As a general trend, Japanese studies find
the D allele appears to be associated with a better antiproteinuric response [77,98,
99], while European studies report either no effect of genotype [83,100,101], or a
poor response associated with the D allele in both diabetic and as non-diabetic renal
patients [102-105]. It should be noted that all of these studies were either
retrospective, or post-hoc analyses of prospective studies. Discrepancies may be due
to differences in study design, patient selection, treatment regimen, such as dose of
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of RAAS activation. In a cross-sectional analysis of Caucasian patients with
proteinuria of mixed origin we found that only in DD subjects the responses of
proteinuria and blood pressure were correlated with the prevailing sodium excretion.
In DD homozygotes, but not II/ID subjects, a high sodium intake was associated with
a poor response to ACE-inhibition [108]. Similar  observations have been made in
Japanese patients with IgA nephropathy [109]. Thus, the relationship between
responsiveness to ACE-inhibition and ACE genotype may be affected by sodium
intake, which may account for some of the above discrepancies. Although these
findings still require confirmation in prospective studies, their implication is that
therapy resistance in patients with the DD genotype, as observed in several
populations, may be ameliorated by dietary sodium restriction.  
Only two studies report the renal hemodynamic response to ACE-inhibition.
No effect of genotype was found in Caucasian proteinuric patients [100], while a
blunted renal hemodynamic response was reported in healthy Japanese DD subjects
[110]. 
The effect of ACE genotype on the renal response to ACE-inhibition appears
to vary with conditions and patient populations. Thus, ACE genotype can only partly
account for individual differences in therapy response, which should encourage  the
search for interaction between ACE genotype with other genetic or environmental
factors. Identification of factors accounting for discrepancies between studies may
help to explain the mechanism of the relative resistance to therapy in the DD
genotype in some populations and thus guide strategies to improve therapy response
in these populations.
The effect of ACE I/D genotype on the hormonal responses to ACE-inhibition
has thus far been studied only in healthy volunteers [111] and in essential
hypertension [112,113]. In these studies the blood pressure response to ACE-
inhibition was not affected by ACE genotype. The decrease in serum ACE after ACE-
inhibition, however, and the rise in plasma renin and the decreases in AngII and in
AT1 receptor expression were more pronounced in DD homozygotes [114]. These
hormonal effects are of potential clinical interest, as they suggest the possibility of
differences between long-term effects on tissue remodelling, and short-term
hemodynamic effects. As such they may explain the possibility of differences in long-
term therapy outcome in different genotypes despite similar short-term hemodynamic
responses. Interestingly, AT1 receptor expression is decreased in II homozygotes
during calcium channel blockade but not during ACE-inhibition [114]. Whether these
differences in response to various  classes of antihypertensives affect therapeutic
benefit remains unresolved. They may indicate that patients with different genotypes
would require different antihypertensive regimens, in terms of the class of
antihypertensive drug-, or the dose regimen. Regarding RAAS  blockade in renal
patients with the DD genotype, it would be particularly interesting to investigate the
efficacy of high-dose ACE-inhibition, AT1 receptor blockade, or their combination.
Such studies might lead to the development of pharmacogenetic principles for
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determining the choice of therapy. It should be emphasized, however, that
substantial empirical evidence from prospective studies is required before such an
approach would be warranted in clinical practice. 
PROGRESSIVE RENAL FUNCTION LOSS AND ACE GENE POLYMORPHISM:
PUTATIVE MECHANISMS  
Elucidation of the mechanisms underlying the renal risk associated with the D
allele is important for the development of strategies for renoprotection. It should be
noted, however, that for the moment it is still uncertain whether the D allele is in fact
causally involved in renal risk, or whether it is a mere risk marker. A clue to possible
mechanisms underlying the increased renal risk lies in the observation that ACE
genotype affects the course of diverse renal disorders, leaving the prevalence of the
disorders (reflecting diverse mechanisms of initial renal damage) largely unaffected.
This suggests effects on common mediators of renal function loss. A common
pathway is thought to play a major role in the progressive renal function loss that
occurs in many renal patients, despite the absence of overt activity of the initial
disorder. Systemic and glomerular hypertension and glomerular protein leakage have
been implicated in this common, vicious spiral that eventually leads to focal
segmental sclerosis, the alleged final common pathway of chronic renal disease
[115].
The renoprotective effect of ACE-inhibitors in experimental and human renal
disease [116,117] support a role of AngII in this common pathway. The hypothesis
that the D allele, by enhanced AngII generation, stimulates this common pathway of
renal damage is attractive for several reasons. First, it could explain why ACE
genotype affects renal prognosis in diverse renal disorders, leaving their prevalence
unaffected. Data on renal morphology in IgA nephropathy, reporting an association
between the D allele and the percentage of glomeruli with global or segmental
sclerosis, despite the absence of differences in histological grade, appear to support
this view [61]. Furthermore, as AngII is also involved in cardiovascular
pathophysiology, it might provide a unifying explanation for the increased propensity
to target organ damage in both the cardiovascular system and the kidney. It should
be mentioned here that the pathophysiology of focal segmental glomerular sclerosis
is noted for its similarity to atherosclerosis [118]. In line with this, the DD genotype is
reported to predispose to hypertensive target organ damage in the cardiovascular
system and in the kidney [119]. Endothelial dysfunction, reported to be associated
with the D allele, may be involved in such an increased vulnerability of the cardio-
renal macro-and micro-vascular bed [120].
While AngII may be involved by the renal and systemic effects discussed




increases endothelial expression of plasminogen activator inhibitor-1 (PAI-1) [121]
and thus may affect fibrinolytic balance. An increased level of PAI-1 may be
associated with an increased risk for myocardial infarction [122] and it has been
suggested that PAI-1 level is be affected by ACE genotype. Whether this bears
relevance for renal disease remains to be established, but in view of the alleged role
of intraglomerular thrombosis in progressive renal function loss [123] this possibility
deserves further consideration.
CONCLUSIONS AND DIRECTIONS FOR THE FUTURE
As is clear from the above overview, in the study of the role of normal genetic
variability in complex multifactorial disease, there are no simple answers.
Understanding the role of ACE genotype in renal disease is still hampered by the
methodological limitations of the available studies. Despite these limitations, the
available evidence supports the view that the D allele is a risk factor for progressive
renal function loss in a spectrum of chronic renal disorders. The ACE I/D genotype
may also affect the therapeutic response to ACE-inhibition in renal patients, but this
interaction may be different in Caucasian as compared to Japanese populations.
Thus, albeit of modest potency and not under all circumstances, ACE genotype is the
first genetic risk factor for progressive renal function loss. More detailed genetic
analysis in genetically homogeneous populations [124] could elucidate the genetic
basis of these renal effects. While large epidemiological studies can serve to define its
overall impact in the renal population, it may be even more important to delineate
under which circumstances, by which mechanisms, and in which patients, ACE (I/D)
genotype exerts an effect on renal risk. It has been pointed out that clinical and
pathophysiological studies, preferably in genetically homogeneous populations, are of
crucial importance to turn the data generated by the new genetic techniques into
clinical benefit [125].
What studies would be needed ? We wish to emphasize the need for truly
prospective studies, i.e. studies in which patients are randomized not only according
to disease and therapy, but also according to genotype. Particular attention should be
given to accurate definition of the renal phenotype and to standardization of
environmental factors such as sodium intake. This could identify environmental
factors that allow ACE genotype to affect renal risk. This is important from a
therapeutical perspective, as environmental factors may be accessible to intervention,
whereas genotype is not.
Elucidation of the pathophysiological mechanisms is important for developing
more effective prevention and treatment. The evidence of increased AngII generation
in the DD genotype supports the hypothesis that the RAAS phenotype plays a role.
Progressive renal and cardiovascular disease share several risk factors, such as
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hypertension, hyperlipidemia and proteinuria, all associated with compromised
endothelial and microvascular function which may constitute a common pathway for
progressive target organ damage. As ACE I/D genotype appears to be an additional
common risk factor, it might be fruitful to focus on such pathways common to renal
and cardiovascular disease. If increased tissue action of AngII is indeed involved,
treatment with AT1 receptor blockers, high-dose ACE-inhibition, or their combination
may increase renoprotective efficacy in patients with the DD genotype. 
In conclusion, ACE I/D genotype has been identified as the first genetic risk factor for
the progression of renal disease in a variety of renal disorders. The present challenge
is to identify the underlying mechanisms and to explore the therapeutic implications,
in order to be able to use this new knowledge for improving the prognosis of patients
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The rate (slope) of long-term renal function loss is the best indicator of renal
prognosis. For practical reasons however it is not usually applied as a parameter for
inclusion or randomization in studies on long-term renal function loss. We hypothesized
that the prior slope affects the outcome of these intervention studies.
We assessed the impact of pre-intervention renal function decline by analyzing
pre-intervention renal function loss (during standard medical care) in 60 non-diabetic
renal patients in whom an intervention study was performed (enalapril vs. atenolol), and
a post-hoc analysis on ACE I/D polymorphism was carried out. 
The pre-intervention slope correlated with the slope improvement during
intervention (r= -0.78, p<0.0001), indicating better treatment benefit in patients with a
steep slope before intervention. For enalapril and atenolol the slopes during intervention
were similar. Despite a similar creatinine clearance at baseline however, pre-intervention
slope was not well matched, i.e -3.7 ml/min/yr before enalapril versus -2.2 ml/min/yr
before atenolol (p=0.053). A significant slope improvement was found during enalapril
(intervention slope -1.9 ml/min/yr, p<0.02) but not during atenolol (intervention slope -
1.8 ml/min/yr). In the analysis according to genotype the slope during intervention was
significantly steeper in the DD genotype, suggesting treatment resistance. However, a
significant improvement in slope was found only in DD genotype (-6.1  to 3.0 ml/min/yr,
p=0.001), versus ID (-1.8 to -1.4 ml/min/yr) and II (-2.1 to -1.5 ml/min/yr). On
multivariate analysis pre-intervention slope was the main predictor of slope improvement
(p<0.001) and of the intervention slope (p=0.005), respectively.  
Pre-intervention slope is the main determinant of renoprotective benefit,
overruling the effect of specific pharmacologic intervention or genotype. Differences in
pre-intervention slope can induce bias in intervention studies. For future intervention
studies, allocation according to pre-intervention slope can preclude inclusions of non-
progressors, and may allow to conduct more valid studies in smaller number of patients. 
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INTRODUCTION
In chronic renal disease renal function usually deteriorates progressively
towards end stage renal failure. Major effort was made over the last decade to
develop and evaluate renoprotective strategies by long-term intervention studies in
man [1-7]. Whereas the rate of renal function loss is usually fairly constant for
individual patients, it varies greatly between patients [8]. Theoretically, for studies on
progressive renal function loss it would be best to include or randomize patients
according to their prior rate of renal function loss, as the main predictor for renal
prognosis. This could ensure an equal allocation of patients with high or low risk for
progression to different treatment groups, and it could preclude inclusion of non-
progressors. Not surprisingly, such approach has not been applied for comparative
parallel trials, because of obvious practical problems in obtaining data on the rate of
renal function loss before intervention. Therefore, patients are usually included
according to baseline cross-sectional parameters, like renal function, blood pressure,
and proteinuria as indirect indicators of renal prognosis.
We hypothesized that the prior rate of renal function loss might affect the
outcome of studies on progressive renal function loss and that accordingly, neglect of
this information could bias the interpretation of the results of intervention. To test
this hypothesis, we analysed the impact of pre-study rate of renal function decline on
the outcome of a 4-year prospective parallel intervention with atenolol versus
enalapril [9]. In this prospective study progression rate was not different for the two
regimens. In a post-hoc analysis of these data we found a faster progression rate in
patients with ACE DD genotype [10]. Remarkably, the present analysis revealed that
prior rate of renal function loss was the main determinant, not only of rate of renal
function loss during intervention, but notably also of treatment benefit. Moreover, the
interpretation of the data on the role of ACE genotype in treatment benefit was put
into a quite different perspective.
Methods
In the previously published report, 89 patients with non-diabetic renal
insufficiency were studied according to a prospective parallel randomized double-blind
design [9]. In short, four weeks after withdrawal of antihypertensive drugs, baseline
measurements were obtained. Inclusion criteria were a creatinine clearance of 30-90
ml/min and a diastolic blood pressure of more than 80 and less than 110 mmHg.
Patients were randomized to treatment with atenolol or enalapril (starting dose 50/10
mg o.i.d. respectively). Drug dose was titrated on a goal diastolic blood pressure of 10





For the present analysis, data on the period before study entry (during regular
patient care) were retrospectively collected from patient records. Subjects were included
if at least 1 year of follow-up during the pre-intervention period was available, with 3 or
more data points for each parameter. At each visit, blood pressure was measured
(during baseline and during the intervention period by automated device, Dynamap®),
24 hour urine was collected for determination of proteinuria (by pyrogallol red
molybdate method) and creatinine. Blood was drawn for creatinine measurement (by
standard autoanalyzer, SMA-C, Technicon®) to calculate creatinine clearance. Values
were corrected for body surface area /1.73 m2. ACE genotype was determined by PCR
method using two different specific insertion primers to confirm putative DD genotypes
and prevent mistyping as previously described [11]. 
Data on creatinine clearance, blood pressure and proteinuria are given as mean
± 95% CI during retrospective and prospective follow-up. The blood pressure and
antiproteinuric responses were analysed as the change from baseline, that is, four weeks
after withdrawal of prior treatment. The baseline characteristics of the original and the
present analysis study group were compared by Chi-square test (gender, age, genotype,
treatment and type of disease) and non-parametric Mann-Whitney U test (continuous
variables). Differences between atenolol/enalapril and genotype groups were tested for
slope, MAP and proteinuria by non-parametric ANOVA test. Mann-Whitney test was used
to detect differences between two subgroups separately. Progression of renal function
loss was estimated for each individual by calculating the slope of creatinine clearance
versus time by the least squares regression method. The slope of renal function during
the prospective study period is presented as the slope calculated from the data points as
of three months onwards, to eliminate the influence of the initial effect of
antihypertensive treatment on renal function [9]. 
Paired non-parametric Wilcoxon test was used to test the differences
between blood pressure, proteinuria and slope, respectively, during the pre-
intervention and the intervention period. Treatment benefit was expressed as slope
improvement, i.e the difference between the pre-intervention slope and the
intervention slope (delta slope) calculated by subtracting the pre-intervention slope
from the intervention slope. In addition, the determinants of the intervention slope,
and of delta slope, respectively, were analysed by multiple regression analysis. To
this purpose, intervention slope and delta slope were modelled as respective outcome
variables, with the pre-intervention slope and genotype as covariates, adjusting for
baseline renal function, baseline and follow-up  MAP and proteinuria. A two-sided p-
value less than 0.05 was considered to be significant.
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RESULTS
ACE genotype was obtained in 81 patients [10]. A total of 60 patients could be
included in the present analysis. Mean follow-up was 59.2 ± 5.5 months. The other 21
patients all entered the prospective trial within one year after the diagnosis of renal
disease. Thus, the pre-intervention period was too short to allow a valid slope
assessment. Baseline characteristics in the present study sample were not significantly
different from the original population (Table I). 
Table I. Patient characteristics before start of the intervention study, i.e. after withdrawal of previous
medication (mean ± 95 % CI). Data are given for the original study and for the patients in the
present analysis.
 
original study (n=81) present analysis (n=60)
age (years) 49 ± 3 49 ± 3
creatinine clearance (ml/min) 55.1 ± 5.1 56.3 ± 6.0
MAP (mm Hg) 110 ± 3 108 ± 2
proteinuria (gr/day) 1.4 ± 0.5 0.9 ± 0.4
sodium excretion (mmol/day) 126 ± 17 127 ± 13
DD / ID / II (n) 17 / 37 / 27 15 / 24 / 21
use of antihypertensives, > 1 (n) 57 41
diuretics (n) 20 15
beta-blockers (n) 32 23
ACE-inhibitors (n) 20 14
miscellaneous (n) 9 6
glomerulosclerosis/hypertension (n) 33 24
IgA nephropathy (n) 5 4
urolithiasis/reflux (n) 11 9
polycystic kidney disease  (n) 11 9





Table II.  Rate of renal function loss, blood pressure and proteinuria during the pre-intervention and the 
 intervention period (mean ± 95 % CI). Baseline renal function, blood pressure and 












age (years) 50 ± 3 48 ± 3 49 ± 4 49 ± 2 49 ± 3
gender  (male /female) 21/10 15/14 9/6 13/11 11/10
genotype (DD/ID/II) 9/ 11/11 6/13/10
slope (ml/min/yr) -3.7 ± 1.1 -2.2 ± 1.2 -6.1 ± 1.8* -1.8 ± 1.0 -2.1 ± 1.1
mean MAP (mmHg) 108 ± 3 107 ± 4 110 ± 5 106 ± 4 108 ± 3
mean proteinuria (gr/day) 0.9 ± 0.4 1.0 ± 0.6 1.3 ± 0.9 1.0 ± 0.6 0.7 ± 0.4
baseline
creatinine clear. (ml/min) 57.8 ± 10.1 56.9 ± 7.8 45.9 ± 11.9 50.1 ± 6.3 71.8 ± 10.4*
MAP (mmHg) 108 ± 3 111 ± 6 113 ± 5 106 ± 5 112 ± 5
proteinuria (gram/day) 1.1 ± 0.5 1.7 ± 0.8 1.9 ± 1.1 1.5 ± 0.9 1.1 ± 0.6
intervention period
slope (ml/min/yr) -1.9 ± 0.8# -1.8 ± 0.7 -3.0 ± 0.8*/# -1.4 ± 0.9 -1.5 ± 1.0
mean MAP (mmHg) 94 ± 3 $ 96 ± 5 $ 98 ± 5 $ 94 ± 5 $ 95 ± 4 $
mean proteinuria (gr/day) 0.5 ± 0.3 $ 1.1 ± 0.6 $ 1.1 ± 0.7 $ 0.9 ± 0.6 $ 0.5 ± 0.3 $
* p<0.05 compared to other genotypes / # p<0.05 compared to pre-intervention study period
$ p<0.05 compared to baseline.
For the groups randomized to enalapril and atenolol (Table II, left part) baseline
creatinine clearance, MAP and proteinuria were not significantly different. During
intervention, in accordance with our previous report, MAP, proteinuria and rate of renal
function loss were similar with enalapril and atenolol [9]. However, the pre-intervention
rate of renal function loss tended to be more rapid in the enalapril group, although the
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difference did not quite reach statistical significance (p=0.053). Also, only the enalapril
group had significantly better slope during intervention (p=0.018). 
The corresponding data for a break-up according to ACE genotype (Table II,
right part) reveal a higher creatinine clearance in the II genotype at baseline, with
similar MAP and proteinuria for the three genotypes. During intervention, in accordance
with our previous report, MAP and proteinuria were similar for the genotypes, with a
worse rate of renal function loss in DD homozygotes [10]. Also, pre-intervention rate of
renal function loss was significantly higher in the DD genotype. However, in the DD
genotype, a significant benefit of intervention was apparent from the improvement in
rate of renal function loss during intervention (p=0.0012, Figure 1). No such
improvement was found in other genotypes. 
Figure 1. Creatinine clearance slopes (ml/min/1.73 m2) for DD, ID and II genotype during
 the pre-intervention and the intervention period. The pre-intervention slope is drawn
by taking baseline renal function as reference and calculating renal function loss

































For the population as a whole, the pre-intervention slope correlated with the
improvement in slope during the intervention period (r= -0.78, p<0.0001, Figure 2),
indicating a larger benefit of the trial regimen in patients with rapid renal function loss
before intervention. A similar correlation was present for the enalapril (r= -0.72,
p<0.0001) and atenolol (r= -0.64, p<0.0001) group and for each genotype group
separately (DD; r= -0.90, p< 0.0001, ID; r= -0.66, p=0.0008, II; r= -0,71, p=0.0004).
On multivariate analysis the pre-intervention slope was an independent
predictor of the intervention slope (P=0.005) and the delta slope (P<0.001),
respectively, overruling the effect of ACE genotype, the change in MAP and
proteinuria. If the pre-intervention slope was left out of the model, ACE DD genotype
was an independent predictor of the intervention slope (P=0.048) and delta slope
(P=0.041), respectively.
Figure 2. Correlation between change in creatinine clearance slope (the intervention period slope
minus the slope during the pre-intervention period) and the slope during the pre-
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DISCUSSION
This study demonstrates the impact of the pre-intervention rate of renal
function decline, a neglected parameter in studies on long-term renoprotective
intervention. We found that pre-intervention rate of renal function loss is a major
predictor not only of the subsequent rate of renal function loss during intervention,
but also of therapeutic benefit in terms of slope improvement. 
Treatment benefit was largest in patients with rapid renal function loss before
intervention and smallest or absent in those with a low renal risk to start with.
Although this finding is intuitively obvious, it has never been formally demonstrated
with respect to renoprotective intervention. This observation clearly parallels the
findings in intervention studies in hypertension, where the a priori risk determines the
benefit of antihypertensive treatment [12]. A post-hoc analysis from the MDRD study
suggested that benefit of protein restriction depends on the underlying rate of renal
function loss, without, however, providing data on rate of renal function loss without
intervention [13]. 
We found that pre-intervention slope was the main predictor of the slope
during intervention, and – on multivariate analysis - outweighed the effect of
proteinuria and blood pressure. This might come as a surprise, considering the large
body of evidence on the impact of baseline proteinuria and blood pressure as renal
risk factors [1-4, 16]. It should be noted, however, that in other studies the
predictive value of proteinuria and blood pressure was not tested for its
independency from prior rate of renal function loss. 
We used two outcome parameters, the intervention slope, and the delta
slope, respectively. The delta slope is a derived variable with pre-intervention slope
as a component. thus the possibility of bias due to mathematical coupling between
pre-intervention slope and delta slope should be considered [14-15]. Mathematical
coupling can induce bias mainly when accuracy and repeatability of measurements
are low, and when the range of obtained values is small. In our analysis however,
specific care was taken to obtain slope data with high accuracy and repeatability, by
minimum requirements for number of data points and duration of pre-intervention
period. Thus, a single slope value reflects multiple measurements (mean number of
data points 11), which limits the risk that the observed relationship between pre-
intervention slope and delta slope reflects mathematical coupling in stead of a
pathophysiologically meaningful association. Whereas mathematical coupling cannot
completely be excluded as a confounder for delta slope, pre-intervention slope was
also the main predictor for the slope during intervention. As pre-intervention slope
and intervention slope are mathematically independent, the conclusions of this
analysis cannnot be biased by mathematical coupling. 
We previously reported the similar rate of renal function loss during enalapril and
atenolol [9]. The present analysis however, shows that randomisation to enalapril or




renal function loss, despite similar renal function, blood pressure and proteinuria at
baseline. Whereas the difference in prior rate of renal function decline between the
groups did not quite reach statistical significance - because of a wide scatter in
individual slopes - this incomplete match may well have biased the estimation of
treatment benefit from the parallel data. This is suggested by the significantly
improved slope during intervention as compared to pre-intervention in the enalapril
group only. As the intervention slopes were similar for the two regimens, the
difference between the groups appears to be related to the slightly higher prior rate
of renal function loss in the enalapril group. 
The impact of prior rate of renal function decline was even more remarkable
for the analysis of the effect of ACE genotype on study outcome. When assessed
from the parallel intervention data only, the steeper slope in the DD genotype during
intervention suggests lack of renoprotective benefit in these subjects. However, the
pre-intervention data revealed that slope improvement was most readily apparent in
DD homozygotes. This treatment benefit in DD subjects is in accord with other recent
findings [15] and – according to our data – may be explained by their steeper pre-
intervention slope rather than by ACE genotype as such, as slope improvement
closely correlated with the pre-intervention rate of renal function decline
independently of genotype. The steeper slope in DD genotype is in accord with
several studies in diabetic and non-diabetic nephropathy [10, 17-22] but at variance
with a recent study in proteinuric patients with non-diabetic renal disease [15]. In
their study however, both proteinuria and renal prognosis were much worse than in
our population, and the relative impact of phenotypic and genetic risk factors may be
different under such circumstances [23].   
The pre-intervention data in this study were obtained retrospectively. Thus,
the potential flaws of a post-hoc analysis, and notably selection bias should be
considered. From the original 81 patients, 21 could not be included. However, the
only reason for non-inclusion of these patients was that the pre-intervention period
was less than a year – precluding accurate assessment of the pre-intervention slope.
Thus, no patients were lost to follow-up, and the intention-to-treat principle was not
violated. Therefore, whereas we cannot exclude selection bias completely, we
consider it unlikely that it plays a major role in the present results.   
The predictive value of pre-intervention rate of renal function decline for
treatment benefit is of clear relevance for future studies on renoprotective
intervention. This holds particularly true for trials with relatively small numbers of
patients, where inclusion of non-progressors may have a relatively large impact. Our
data suggest that it would be fruitful to consider prior rate of renal function loss (if
available) as a randomization parameter, as randomization on cross-sectional
parameters may not warrant a sufficient match for the risk for renal function loss.
Use of such longitudinal data may substantially enhance the power of studies to
detect differences between treatment arms and thus reduce the required number of
patients. For clinical purposes, it is important that our data show that a rapid rate of
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renal function loss should not be considered a reason for therapeutic nihilism, but to
the contrary identifies patients that particularly benefit from intervention treatment.
In conclusion, pre-intervention rate of renal function loss is a main determinant of
subsequent renoprotective benefit. It may considerably affect the outcome and the
interpretation of studies on chronic renal function loss. Considering prior rate of renal
function loss as a randomization parameter, albeit cumbersome, may enhance study
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Background: The renal response to ACE-inhibition is known to vary between
individuals. The ACE genotype is a determinant of the ACE levels in plasma and
tissue, and therefore might affect the renal response to ACE-inhibition in renal
patients. 
Methods: To test this hypothesis we studied the short-term response to ACE-
inhibition (enalapril or lisinopril 10/20 mg/d) in 61 stable proteinuric patients (>1.0
g/day) in relation to the ACE genotype (DD: N=16, ID N=32, II N=13).
Results: Baseline values were not significantly different for the three groups.
ACE-inhibition significantly lowered proteinuria, mean arterial pressure, GFR and FF in
all genotype groups. The reduction in proteinuria, MAP, GFR and FF was not different
between the genotype groups. ERPF rose significantly and to the same extent in all
three groups.
Conclusions: We conclude that in proteinuric patients the short-term
responses to ACE-inhibition of proteinuria, blood pressure, and renal hemodynamics
are not determined by ACE genotype. Thus, ACE gene polymorphism does not
account for the known interindividual variation in the short-term renal response to
ACE-inhibition.
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INTRODUCTION
Angiotensin-converting enzyme (ACE) inhibitors exert a variety of
renoprotective effects in renal patients. They reduce blood pressure and proteinuria
(1), they induce renal vasodilation with a reduction in filtration pressure, and they
retard the rate of long-term renal function loss (2).  A considerable interindividual
variability in the renal responsiveness to ACE-inhibition, however, is found in many
studies (3,4). This variability is apparent even in studies where sodium and protein
intake, known modifiers of the renal responses to ACE-inhibition (5,6), are well
standardized (7). Thus, individual factors may account for the differences in the renal
responses to ACE-inhibition. 
Some years ago an insertion/deletion (I/D) polymorphism was detected on
the gene coding for ACE in man, located on an intron at chromosome 17 and
consisting of a 287 basepair fragment (8). This polymorphism appeared to be a major
determinant of plasma ACE levels (9). Individuals with the DD genotype have the
highest ACE levels; those with the II genotype the lowest. Interestingly, in individuals
with the DD genotype ACE levels appear to be elevated in tissue as well (10,11). 
The differences in plasma and tissue ACE activity associated with the ACE-
genotype might affect the response to ACE-inhibition, and thus might be a
determinant of the interindividual differences in the renal response to ACE-inhibition.
In the present study, therefore, we investigated whether in proteinuric renal patients
the short-term responses to ACE-inhibition of proteinuria, blood pressure and renal
hemodynamics were affected by the ACE genotype. 
METHODS
Patients and protocol
ACE genotype was determined in all patients in whom ACE-inhibition had
been instituted as antiproteinuric therapy according to standardized protocols. All
patients had non-diabetic renal disease and a proteinuria exceeding 1 gram/day.
Before enrollment, proteinuria, blood pressure and renal function were stable. None
of the patients suffered from diseases other than their renal disorder. The studies
were performed on an ambulatory basis. During the studies patients adhered to a
diet containing 1 gram protein per kg bodyweight and a moderate sodium restriction
of 50-100 mmol/day. Before enrollment all antihypertensive medication, including
diuretics and other antiproteinuric medication, was withdrawn for at least four weeks.
At the end of this control period, blood pressure, renal hemodynamics and urinary
protein excretion were determined. Subsequently the patients were instituted on




patients the dose was titrated to 20mg/day to obtain adequate blood pressure control
(diastolic blood pressure < 90 mmHg). The patients regularly visited the outpatient
clinic for measurement of blood pressure, routine blood chemistry, and 24-hour
urinary excretion of protein. After stabilization of the antiproteinuric response (that is,
after 4 to 12 weeks) measurement of renal hemodynamics was repeated. All subjects
gave their informed consent to the initial protocols which were approved by the local
hospital ethical committee.
Clinical and laboratory procedures
During each visit blood pressure was assessed in the supine position after 5
minutes of supine rest. Mean arterial pressure was calculated as diastolic pressure
plus one-third of the pulse pressure. GFR and ERPF were measured as the clearances
of constantly infused 125I-iothalamate and 131I-hippuran, respectively, and corrected
for inaccurate urine collection as described previously (12). Intrapatient day to day
variation is 2.2 % for GFR and 5 % for ERPF by this method. Both parameters are
expressed per 1.73 m2 body surface area. Filtration fraction (FF) was calculated as
the ratio of GFR and ERPF. Routine blood and urine analysis were determined by
automated multi-analyzer (SMA-C, Technicon ®). Urinary protein was detected with
the pyrogallol red-molybdate method, with an intra-assay coefficient of variation less
than 3.3 % and a interassay coefficient variation of less than 3.0 % (13). ACE
genotype was determined by polymerase chain reaction as described previously (9)
with prevention of mistyping heterozygotes as described by Shanmugan (14). Blood
specimens were collected in heparinized tubes, wereafter DNA could be extracted
from peripheral leucocytes. Genomic DNA was amplified by PCR method. The
amplified genes were separated by agarose gel electrophoresis. 
Data analysis
 
All data are expressed as Wilcoxon estimated median with 95 % confidence
intervals (CI). To test for differences between baseline and ACE-inhibition values a
paired Wilcoxon test was used. To test for differences between the genotype groups
the Kruskall-Wallis non-parametric ANOVA-test followed by a Dunn procedure was
used. Mann-Whitney test was used to detect differences between two genotype
subgroups separately. Statistical significance was assumed at a 5 % level (two-
sided).
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RESULTS
Patients characteristics including histological diagnosis are shown in table I
for the three genotypes. It shows that age and sex distribution were similar in the
three groups. In all three groups there was a preponderance of male subjects. The
frequency of the D-allele was 0.52, which is in accord with the normal frequency in
the Netherlands (15).  
Table I. Patient characteristics
DD (n=16) ID (n=32) II (n=13)
Age (years) 43 (35 to 51) 44 (37 to 46) 45 (36 to 55)
Male/female 12/4 29/3 10/3
Glomerulosclerosis 7 11 7
IgA nephropathy 1 6 3
MGP* 4 8 0
Glomerulonephritis 2 3 0
PCKD* 0 1 1
Miscellaneous 2 3 2
* MGP = membranous glomerulopathy
* PCKD = polycystic kidney disease
Data on proteinuria, blood pressure and renal hemodynamics during baseline
and their responses to ACE-inhibition are shown in table II. Baseline proteinuria was
not different between the groups, despite a tendency for a somewhat higher
proteinuria in patients with the DD genotype. Baseline MAP was similar in the three
groups. In the DD genotype group baseline GFR and ERPF were somewhat lower
than in the other groups but the differences did not reach statistical significance.
Baseline FF was similar in the three groups.
During ACE-inhibition, proteinuria and blood pressure fell to a similar extent
in all groups. A small but significant fall in GFR was noted in all groups without




Table II. Baseline values and % change during ACEi for proteinuria, blood pressure and renal
 hemodynamics (medians and 95 percent confidence interval).
DD (n=16) ID (n=32) II (n=13)
Uprot (g/day) 6.1 (4.8 to 8.7) 4.4 (4.2 to 8.1) 3.6 (2.7 to 8.2)
% change -48 (-68 to -44)* -55 (-62 to -44)* -50 (-63 to -29)*
MAP (mmHg) 105 (100 to 120) 105 (100 to 112) 111 (103 to 117)
% change -14 (-22 to -13)* -13 (-18 to -12)* -12 (-19 to -8)*
GFR(ml/min/1.73m2) 54 (38 to 66) 59 (57 to 82) 77 (54 to 97)
% change -9 (-15 to -4)* -7 (-13 to -3)* -7 (-11 to -2)*
ERPF(ml/min/1.73m2) 242 (177 to 352) 320 (285 to 421) 311 (204 to 413)
% change 8 (4 to 18)* 10 (4 to 13)* 9 (2 to 17)*
FF % 24 (19 to 26) 22 (19 to 23) 24 (23 to 28)
% change -25 (14 to -27)* -17 (-12 to -20)* -16 (-8 to -20)*
* =<0.05, paired Wilcoxon test vs. baseline value 
again without significant differences between the groups. As a consequence, FF fell
to a similar extent in all groups. 
Thus, ACE-inhibition induced significant responses of proteinuria, blood
pressure and renal hemodynamics in all genotype groups. As expected, the
magnitude of the responses varied between individuals. The individual response of
proteinuria, MAP and renal hemodynamic parameters are shown in figure 1; it shows
that no relationship between genotype and the magnitude of any of the responses to
ACE-inhibition was apparent. In some patients the ACE-inhibitor dose was increased
to obtain adequate blood pressure control. The number of dose increments was not
significantly different between the groups (2/13 patients in the DD group, 4/32
patients in the ID group and 1/11 patients in the II group).
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Figure 1. Individual data on proteinuria, MAP, GFR, ERPF and FF at baseline and during
ACE-inhibition. * = p < 0.05; ACE-inhibition versus baseline. Median values





























































In the present study we evaluated whether the short-term responses to ACE-
inhibition of proteinuria, blood pressure and renal hemodynamics were affected by
the ACE genotype in proteinuric patients. We found that the short-term responses of
these parameters to ACE-inhibition were similar for the three genotype groups in this
population. 
Could the lack of association between genotype and the response to ACE-
inhibition in the present study be due to the study design? First, variability in
response could have been introduced by the use of two different ACE-inhibitors (16),
different doses and different periods of treatment. However, all patients were studied
after stabilisation of the antiproteinuric response. Also, we found no differences in the
responses to enalapril and lisinopril in the current study. The number of patients
however, was too small to assess the effects of genotype for the two ACE-inhibitors
separately. It might be, that study conditions should be more rigorously standardized
to detect a difference in response to ACE-inhibition between patients with different
ACE genotypes. If so, this would also implicate, however, that the impact of ACE
genotype on the responsiveness to ACE-inhibition is relatively minor. Second, the
effects of patient selection should be considered. Patients with overt cardiac disease
were excluded, which may have introduced selection bias in view of in the increased
cardiovascular risk in patients with the DD genotype. In addition, the course of renal
function had to be stable before enrollment to avoid that the natural course of the
disease would lead to end stage renal failure within the time span of the study. This
could introduce selection bias by excluding patients with an aggressive natural course
of the renal disease. We therefore cannot reliably exclude that selection bias affected
our results. It is to be noted however that allele frequency and genotype distribution
in our population matches that of the general population in the Netherlands and is in
accord with the Hardy-Weinberg equilibrium. Thus, selection bias, if any, should be
sought in the selective in-or exclusion of patients with risk factors interacting with the
ACE genotype rather than in selection for a particular ACE genotype per se. 
Our findings seem to be at variance with two previous studies, both in
Japanese subjects. Yoshida et al. in mildly proteinuric patients with IgA nephropathy
(n=21) found a significant antiproteinuric response to ACE-inhibition only in DD
patients but not in ID/II patients (17). Moriyama et al. studied 36 patients with
various renal disorders (18),  and found an impaired antiproteinuric response to ACE-
inhibition in patients with the II genotype. These studies, however, only included
small numbers of patients with the DD genotype, a feature that is characteristic of
Northern Asian populations. Not only the differences in study design, therefore, but
also differences in genetic background preclude a straightforward comparison of their
data with ours. 
The impact of ACE genotype on the short-term responses to ACE-inhibition
has also been assessed in subjects without renal disease. Healthy volunteers with the
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DD genotype had elevated ACE levels and a more pronounced fall in ACE levels after
enalapril, but the fall in blood pressure was similar to that in other subjects (19). In
essential hypertensives the blood pressure response to ACE-inhibition was not
affected by the ACE genotype either (20). These results, be it obtained in populations
without renal disease, are consistent with our finding that ACE genotype does not
affect the short term response of clinical parameters to ACE-inhibition. There is some
evidence, however, that ACE genotype affects the responses of specific components
of the renin-angiotensin system, such as ACE, renin, angiotensin II and the
angiotensin II (subtype 1) receptor to ACE-inhibition in patients with essential
hypertension and in healthy persons (21).
Interest for the role of ACE genotype in renal disease was fuelled by several
recent studies that found the rate of long-term renal function loss to be more rapid in
renal patients with the DD genotype than in patients with the II or ID genotype. This
was found in patients with IgA nephropathy (22,23), diabetic nephropathy in IDDM
(24), as well as NIDDM (25), and in a population of patients with renal disorders of
diverse origin (26). Moreover, a deleterious effect of the DD genotype on the course
of renal disease was also suggested by the finding that IgA nephropathy presents at
an earlier age in patients with the DD genotype (22). The above long term follow-up
studies all evaluated the long-term course of renal function during treatment, either
during regular clinical treatment or according to standardized protocols. The
increased rate of renal function loss in DD genotype patients despite treatment
suggests that current renoprotective regimens are ineffective, or not effective
enough, in reducing the increased long-term renal risk associated with the DD
genotype. In the current study no specific resistance to ACE-inhibition was present in
proteinuric patients with the DD genotype, however, we only studied short-term
parameters. 
In conclusion, ACE genotype does not determine the short-term renal
response to ACE-inhibition in stable proteinuric patients. Therefore, the interindividual
variability in response to ACE-inhibition cannot be explained by ACE gene
polymorphism in this population. To elucidate the role of ACE genotype in renal
pathophysiology and in renal responsiveness to therapy studies are needed on the
short- and long-term effects of renoprotective regimens, such as ACE-inhibitors and
angiotensin II receptor antagonists in larger study populations with various types of
renal disease and different levels of proteinuria with particular focus on the
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ACE-inhibition (ACEi) retards renal function loss, but the therapeutic benefit
varies between individuals. Renoprotection is poor in patients with ACE DD genotype.
ACE genotype is reported to affect short-term antiproteinuric response to ACEi, a
predictor of long-term renoprotection, in some studies but not in others. Short-term
responses to ACEi are enhanced by stimulating the renin angiotensin system, i.e
sodium restriction. We hypothesized that the ACE genotype influences sodium
dependency of the response to ACEi. Therefore, we performed a cross-sectional
analysis of short-term responses to ACEi (enalapril or lisinopril) in 88 patients with
stable non-diabetic proteinuria (>1.0 g/day) and variable sodium intake. ACE
genotype distribution was: DD n=25, ID n=40, II n=23. Baseline mean arterial
pressure (108+3; 106+2; 107+2 mmHg, resp) and proteinuria (5.9+0.7; 5.8+0.7;
4.8+0.8 g/day, respectively) were similar for the three genotypes. ACEi similarly
reduced blood pressure (-12+3; -14+1 and -12+2%, respectively) and proteinuria (-
49+5; -55+4, -48+6%, respectively) in the three groups. Interestingly, the responses
to ACEi of proteinuria (r= -0.42, p<0.05) and blood pressure (r= -0.41, p<0.05)
correlated negatively with urinary sodium excretion in DD genotype but not in the ID
(r= -0.05 and r= -0.17, resp) or II genotype (r=  -0.09 and r= -0.08, resp). Thus, in
the DD group, individuals with a high sodium excretion had a less effective response
to ACEi. We conclude that differences in sodium status could account for disparities
between studies on the relationship between ACE genotype and response to ACEi and
that sodium restriction might be a strategy to circumvent treatment resistance in the
DD genotype.




Interventions in the renin-angiotensin system are an important asset to
attenuate or even halt progressive renal function loss [1]. Unfortunately, the
therapeutic benefit of angiotensin-converting enzyme (ACE) inhibition varies between
patients. The efficacy of long-term renoprotection can be consistently predicted by
the short-term renal responses to therapy, that is, an effective reduction of
proteinuria at onset of therapy predicts a favourable course of long-term renal
function, whereas a poor antiproteinuric response predicts progressive renal function
loss [2,3]. 
Some years ago, an insertion/deletion (I/D) polymorphism of the ACE gene
was identified, which appears to be a major determinant of plasma ACE levels [4]. It
was therefore hypothesized that the ACE genotype might be a determinant of the
response to ACE-inhibitor therapy. Interestingly, the ACE DD genotype appears to be
associated with poor long-term renoprotection during ACE-inhibition [5,6]. One would
expect that the short-term antiproteinuric response would also be less effective in the
DD genotype. Thus far, however, studies on the relationship between ACE I/D
genotype and short-term renal responses to ACE-inhibition are conflicting as the D-
allele has been associated with a worse [7-9], a similar [10] or even a better [11,12]
antiproteinuric response. 
We previously found that sodium intake affects the antiproteinuric response
to ACE-inhibition [13]. We therefore hypothesized that interaction between sodium
intake and ACE genotype may be involved in the variability in the short-term
antiproteinuric response to ACE-inhibition. To test this hypothesis we performed a
cross-sectional analysis of the short-term antiproteinuric responses to ACE-inhibition
in relation to sodium status as assessed from urinary sodium excretion. 
METHODS     
Patients and protocol
We cross-sectionally analysed data from 88 non-diabetic patients in whom
ACE-inhibition had been instituted as an antiproteinuric treatment. The patients were
recruited from nephrological centers in the Netherlands (n=55) and in Austria (n=33)
as previously described [7,10]. The studies were performed on an ambulatory basis.
Patient characteristics are given in table I. All patients had non-diabetic renal disease
and proteinuria > 1 gram/day. Before enrollment, proteinuria, blood pressure and
renal function were stable and all antihypertensive medication, including diuretics and
other antiproteinuric medication, was withdrawn for at least four weeks. At the end of




excretion were determined. Subsequently, patients were instituted on either enalapril
(n=73) or lisinopril (n=15) with an initial dose of 2.5 to 10 mg/day. In some patients
the dose had to be increased to obtain adequate blood pressure control (diastolic BP
< 90 mmHg). The patients regularly visited the outpatient clinic for measurement of
blood pressure, blood chemistry and 24-hour sodium and protein excretion. The
values of blood pressure and urinary excretion of sodium and protein obtained after
stabilization of the antiproteinuric response (that is after 4 to 12 weeks) were used
for the present analysis.
Clinical and laboratory procedures
During each visit blood pressure was assessed in the supine position and
after 5 minutes of supine rest. Mean arterial pressure was calculated as diastolic
pressure plus one-third of the pulse pressure. Routine urine analysis was determined
by automated multi-analyzer (SMA-C, Technicon®). Urinary protein was detected
with the pyrogallol red-molybdate method. ACE genotype was determined by
polymerase chain reaction as described previously. To prevent mistyping of
heterozygotes, intron specific primers were used [14]. Blood specimen were collected
in heparinized tubes, whereafter DNA could be extracted from peripheral leucocytes.
Genomic DNA was amplified by PCR and the amplified genes were separated by
agarose gel electrophoresis.
Data analysis 
All data are expressed as means ± SEM. To test for differences between
baseline and ACE-inhibition values the Wilcoxon test for paired data was used.
Differences between genotype groups were tested by the Kruskall-Wallis non-
parametric ANOVA-test followed by a Dunn procedure. Mann-Whitney test was used
to detect differences between two genotype subgroups separately. Correlation
coefficients were analyzed using linear regression analysis. A two-sided p-value less
than 0.05 was considered to be significant.
RESULTS
Table I shows that in this study population genotype distribution (DD 28%,
ID 46%, II 26%) was as expected from the Hardy-Weinberg equilibrium. Age, ACE-
inhibitor dose and duration of treatment until stabilisation were comparable in all
three genotype groups. There were relatively fewer female subjects among the
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heterozygotes. Distribution of the different renal diseases over the genotype groups
was skewed, with less IgA nephropathy among the DD homozygotes and less
membranous glomerulopathy among II heterozygotes. 
Table I. Patient characteristics according to ACE genotype 
genotype DD (n=25) ID (n=40) II (n=23)
age (years) 44 (21 to 69) 43 (18 to 61) 47 (20 to 71)
male/female 16/9 35/5 15/8
ACEi dose(mg/day) 13.3 + 1.5 12.3 + 0.7 10.6 + 0.9
duration of treatment 8.9 + 0.5 8.9 + 0.4 9.4 + 0.6
diagnosis
Glomerulosclerosis 11 14 11
IgA nephropathy 1 9 5
MGP a 6 8 1
Glomerulonephritis 4 4 1
PCKD b 0 1 1
Miscellaneous 3 4 4
a  MGP = membranous glomerulopathy
b PCKD = polycystic kidney disease
Data on proteinuria, blood pressure and sodium excretion during baseline and
their responses to ACE-inhibition are shown in table II. Baseline values for
proteinuria, MAP and sodium excretion were similar in the three groups. During ACE-
inhibition, proteinuria and blood pressure fell significantly in all three groups. These




Table II.  Baseline values and % change during ACE-inhibition for proteinuria, blood pressure and  urinary
 sodium excretion during ACE-inhibition according to ACE genotype (mean ± SEM).
DD (n=25) ID (n=40) II (n=23)
Uprot (g/day) 5.9 ± 0.7 5.8 ± 0.7 4.8 ± 0.8
% change -49.0 ± 5.2 * -55.2 ± 4.1* -47.7 ±5.7 *
MAP (mmHg) 108 ± 3 106 ± 2 107 ±2
% change -12 ± 3 * -14 ± 1* -12 ± 2 *
Usodium (mmol/day) 121 ±11 134 ± 13 147 ± 17
* = <0.05, paired Wilcoxon test vs. baseline value
had been increased to obtain adequate blood pressure control. The number of dose
increments was not significantly different between the three groups.
The relationship between urinary sodium excretion and the individual
responses of proteinuria and blood pressure are shown in figure I. A significant
negative correlation was found between sodium excretion and the responses of
proteinuria and blood pressure in DD homozygotes (r= -0.42, and r= -0.41,
respectively; both p<0.05), that is, in patients with a high urinary sodium excretion
the reductions in proteinuria and blood pressure were less effective. These
correlations were absent in patients with the ID (r= -0.05 and r= -0.17, respectively)
and the II genotype (r= -0.09 and r= -0.08, respectively).
DISCUSSION
In the present study we cross-sectionally evaluated the short-term response
to ACE-inhibition of proteinuria and blood pressure in relation to ACE genotype and
sodium status, as reflected by urinary sodium excretion. The mean reductions of
blood pressure and proteinuria were similar for the three genotype groups.
Interestingly, we found a negative correlation between sodium excretion and the
reductions of both proteinuria and blood pressure in response to ACE-inhibition in
patients with the DD genotype, but not in those with the ID/II genotype.
In renal patients, ACE-inhibition reduces blood pressure, proteinuria and the
rate of renal function loss. The renal response to ACE-inhibition, however, is variable
between individuals [2,3]. ACE I/D genotype has been shown to be a determinant of 
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Figure 1. Correlations between responses of blood pressure (left panels) and proteinuria 



































































































































































long-term renoprotective efficacy of ACE-inhibition [5,6]. Studies on the short-term
responses to ACE-inhibition in relation to ACE genotype, however, provided
conflicting results [7-12]. Differences in study design, patient selection, genetic
background of the study populations and genotype distribution may have contributed
to these discrepancies. The short-term responses of blood pressure and proteinuria
to ACE-inhibition are known to be enhanced by dietary sodium restriction [13] as well
as by co-treatment with a diuretic [15]. This enhancement is thought to be due to
the stimulation of the renin-angiotensin system that results from sodium depleting
measures, which increases the contribution of the effector hormone angiotensin II in
the maintenance of blood pressure and proteinuria. Differences in ACE-activity and
angiotensin II generation [16], as associated with ACE genotype, might enhance the
effects of sodium depleting measures. In the present study we investigated whether
differences in sodium status might interact with the association between ACE I/D
genotype and the therapeutic response to ACE-inhibition. 
Interestingly, a significant negative correlation between the responses to
ACE-inhibition and urinary sodium excretion was found in the DD genotype only.
Thus, in patients with the DD genotype, ACE-inhibition was less effective in those in
whom sodium excretion was high. In the other patients the reduction of proteinuria
and blood pressure was equally effective in those with a low and in those with a high
sodium intake. If these findings may be extrapolated to other studies, they would
imply that therapy resistance to ACE-inhibition can expected to be found in DD
homozygotes in study populations on high sodium intake, whereas therapy
responsiveness will be similar for the different genotypes when dietary sodium is
restricted. In support of this assumption, Kawamura et al. made observations similar
to ours in a population with IgA nephropathy [17].
Do our results also implicate that the response to ACE-inhibition is sensitive
to sodium intake only in patients with the DD genotype? In studies where sodium
intake was prospectively altered with each patient as his own control, we found that
sodium restriction consistently potentiated the responses of blood pressure and
proteinuria during ACE-inhibition [13]. The present data cannot directly be compared
with the earlier findings as, first, the present data relate to inter-individual differences
whereas the previous studies assessed intra-patient variability. Also, in the current
study sodium excretion presumably reflects day-to-day variations in sodium status
rather than a consistent alteration in sodium intake as obtained in the earlier studies
where sodium intake was prospectively altered. Thus, the present data do not allow
to draw conclusions as to the individual enhancement of the response to ACE-
inhibition by sodium restriction. We previously found that both the individual
response to ACE-inhibition and the additional benefit of sodium depletion display
distinct inter-individual variability. Whereas the present data suggest that individuals
with the DD genotype will benefit from the potentiating effect of sodium restriction
more than other patients, this assumption clearly requires prospective confirmation.  
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Our study presents a post-hoc analysis of cross-sectional data in patients in
whom ACE-inhibition had been prospectively instituted as antiproteinuric treatment.
Can this design have affected our results? First, caution is warranted in the
interpretation of the correlation between sodium excretion and proteinuria as errors
in the collection of 24-hour urine could mimick such a relationship and thus elicit a
false-positive result. In the DD patients however, we also found a significant
correlation between sodium excretion and blood pressure response. As the latter
parameter is not affected by collecting errors we consider it unlikely that the findings
in DD patients represent such a false-positive finding. Variability in response could
have been introduced by the use of different ACE-inhibitors, different doses and
different duration of treatment, but these parameters were similar for the three
genotype groups. Patient selection should also be considered. First, the exclusion of
patients with non-stable renal function might have introduced selection bias.
Moreover, renal diagnoses were not evenly distributed over the genotype groups.
Finally, our patients were derived from a Dutch and an Austrian population,
respectively, introducing the possibility of differences in overall genetic background.
As the relatively small overall number of patients precludes a valid analysis for these
variables, we cannot exclude the possibility that patient selection affected our
findings.
In conclusion, the current study shows that the relationship between
responsiveness to ACE-inhibition and ACE I/D genotype is influenced by the prevalent
sodium intake. This cross-sectional finding may explain discrepancies between data
published thus far. Moreover, it suggests that in patients with the DD genotype
therapy resistance to ACE-inhibition may be related to excess sodium intake. In view
of the poor long-term renoprotective efficacy of ACE-inhibition in patients with the DD
genotype it would be of great interest to develop strategies to improve therapy
response. Further studies prospectively testing the effect of dietary sodium restriction
on therapy response in relation to ACE I/D genotype may provide an outlook on
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ACE-activity is increased in DD genotype but its functional significance for
renal function is unknown. We reported a blunted response of blood pressure and
proteinuria to ACE-inhibition in DD renal patients during high sodium intake. We
therefore hypothesized that sodium status affects phenotype in ACE I/D
polymorphism. 
We studied the effects of angiotensin I (angI) and angiotensin II (angII) in
27 healthy subjects, both during a low (50 mmol Na+/day) and liberal (200 mmol
Na+/day) sodium intake. Baseline mean arterial pressure (MAP), renal hemodynamics
and RAAS parameters were similar for all  genotypes on either sodium intake.
During liberal sodium the rise in MAP, renal vascular resistance (RVR) and
aldosterone level during angI infusion (8 ng/kg/min) was significantly higher in DD
genotype as compared to ID and II genotype (all parameters given as % change ±
95% CI) , with a mean MAP increase of 22 ± 2 (DD), 13 ± 5 (ID) and 12 ± 6 (II)
mmHg (p<0.05), a mean increase in RVR of 100.1 ± 19.7 (DD), 73.0 ± 16.3 (ID) and
63.2 ± 16.9 (II) (p<0.05)  and an increase in aldosterone of 650 ± 189 (DD), 343 ±
71 (ID) and 254 ± 99 (II) (p<0.05). Also, the fall in GFR was more pronounced in DD
genotype with a mean decrease of 17.9 ± 4.7 (DD), 8.8 ± 3.4 (ID) and 6.4 ± 5.9 (II)
(p<0.05). The ERPF, plasma angII and PRA levels were similar for the genotypes. In
contrast, during low sodium intake, the responses to angI were similar for all the
genotypes. The responses  to angII were also similar for all genotypes on either
sodium intake. 
In conclusion, the responses of MAP, renal hemodynamics and aldosterone to
angI are enhanced in DD genotype, during liberal but not during low sodium intake.
These results support presence of gene-environment interaction between ACE
genotype and dietary sodium.




The renin-angiotensin aldosterone system (RAAS) plays an important role in
the regulation of blood pressure, volume homeostasis and cardiovascular and renal
pathophysiology. Angiotensin-converting enzyme (ACE) is an important enzyme of
the RAAS as it converts angiotensin I (angI) into angiotensin II (angII).  The gene
coding for ACE is subject to an insertion/deletion polymorphism that is a main
determinant of plasma [1] and tissue ACE levels [2-4]. ACE levels are highest in the
DD genotype, lowest in II genotype and intermediate in heterozygotes [1]. 
A large number of studies addressed the role of ACE genotype as a candidate
gene for cardiovascular and renal organ damage. Whereas many studies support a
role for the D-allele as a risk factor for cardiovascular or renal target organ damage
[5-13], other studies provided conflicting results [14-16]. Data on the response to
ACE-inhibition are conflicting as well [17-20]. Increased conversion of angI to angII
has been suggested as a mechanism underlying cardiovascular and renal differences
between subjects of different ACE genotype. An increased pressor response to angI
has been reported in the DD genotype, but other studies provided conflicting
outcomes. [21-23]. So far, no data are available on the effect of ACE genotype on
the renal responses to angI. In the present study, therefore, we studied the effect of
ACE genotype on the responses of renal hemodynamics, as well as blood pressure
and RAAS hormones, to angI in healthy volunteers. 
We previously reported a blunted response of blood pressure and proteinuria
to ACE-inhibition in renal patients with the DD genotype as compared to II and ID
genotype among subjects with a high sodium intake, but not in subjects with a low
sodium intake [24]. This led us to hypothesize a gene-environment interaction
between dietary sodium intake and ACE I/D polymorphism. To test this hypothesis,
all subjects were studied twice: in balance on a liberal as well as a low sodium intake. 
SUBJECTS AND METHODS
Subjects
Twenty seven healthy Caucasian volunteers (age between 18 and 35 years)
were included (Table 1). The study was approved by the local medical ethical
committee and all participants gave written informed consent. All had a medical
history without significant disease and physical examination was unremarkable.
Blood count, serum creatinine, electrolytes and liver enzymes were normal. All had a
mean systolic blood pressure lower than 140 mm Hg and a diastolic blood pressure




Table 1. Baseline characteristics of volunteers during low and liberal sodium diet. Mean ± 95 CI are given.
DD ID II
N 10 10 7
Age (years) 26.4 ± 2.3 22.4 ± 1.3 26.1 ± 4.1
M/F 7/3 9/1 4/3
Low sodium diet
Body weight (kg) 72.6 ± 6.3 76.9 ± 5.9 67.6 ± 8.8
Urine Na+ (mmol/day) 50 ± 19 54± 16 44 ± 21
Urine K+ (mmol/day) 77 ± 14 83± 13 73 ± 18
ACE (U/L) 27.6 ± 3.6* 19.3 ± 3.0 16.1 ± 2.6
K+ (mmol/l) 4.2 ± 0.2 3.9 ± 0 4.0 ± 0.2
Liberal sodium diet
Body weight (kg) 74.6 ± 5.6† 77.0 ± 6.0 68.4 ± 8.5
Urine Na+ (mmol/day) 252 ± 38† 225 ± 25† 229 ± 40†
Urine K+ (mmol/day) 81 ± 18 79 ± 16 80 ± 9
ACE (U/L) 27.6 ± 3.4* 18.7 ± 3.8 18.0 ± 3.9
K+ (mmol/l) 4.0 ± 0.2 4.2 ± 0.2 4.2 ± 0.3
* = p < 0.05  compared to other genotypes
† = p < 0.05 compared to low sodium
 
Study design
Subjects were studied on two separate occasions, that is during a low (50
mmol/day) and during a liberal (200 mmol/day) sodium diet. For each study day,
subjects were instructed to  maintain the prescribed sodium diet during the  7 days
preceding the study day. The diet period was set at 7 days. Sodium restriction
induces RAAS activation within 3 days, with concurrent sodium balance [25]. A period
of 7 days has been shown to be sufficient for a stabilization of circulatory hormones
[26]. The sequence of the diet was prescribed in randomized order. Potassium intake
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was standardized at 100 mmol/day for both periods. To check for dietary compliance,
two 24-hour urine  samples were collected at day  5 and 7 after the start of the diet.
No differences in sodium excretion or body weight ocurred between day 5 and 7,
indicating a stable sodium balance at the time of the experiment. The 24-hour urine
excretion at day 7 is given in table 1. Female subjects were tested in the mid-luteal
phase of their menstrual cycle. Having refrained from food, alcohol, drinking and
strenuous exercise for twelve hours, subjects reported at the research unit at 8.00
AM Two intravenous canulas were inserted into each forearm for infusion and
drawing of blood samples. During the whole study subjects remained in semi-
recumbent position. All subjects were given 250 ml of  oral fluids each hour and a
meal of similar caloric content each two hours. Sodium intake during the study day
was adjusted according to the prescribed diet. To ensure sufficient urine output,
glucose 5% (250 ml/hour) was administered in the right antecubital vein. The
ensueing waterloading is not expected to suppress RAAS parameters to a relevant
extent, in contrast to water and saline loading [27, 28]. Blood samples were drawn at
8.00 AM, at 10.00 AM, and from there each hour until 6.00 PM. From 12.00 AM to
2.00 PM angI (CLINALFA  AG, Switzerland) was administered in the left antecubital
vein, in a dose of 4 ng/kg/min. in the first hour and 8 ng/kg/min. in the second hour.
This was followed by a washout period from 2.00 PM to 4.00 PM. To test whether
possible differences in angI response might be due to differences in sensitivity to
angII, angII (CLINALFA  AG, Switzerland) was administered from 4.00 PM to 6.00 PM
in a dose of 4 ng/kg/min. in the first hour and 8 ng/kg/min. in the second hour.
Test procedures
Blood pressure, expressed as MAP, was measured with an automated device
(Dinamap) at 15 minutes interval, except during angI and angII infusion,  when
blood pressure was measured every 5 minutes. Serum electrolytes, creatinine, liver
enzymes were determined by automated multi-analyzer (SMA-C, Technicon). ERPF
(effective renal plasma flow) and GFR (glomerular filtration rate) were measured
according to a previously described method using a constant infusion of 125I-
iothalamate and 131 I-hippurate, respectively [29]. The coefficients of variation for
GFR and ERPF are 2.2 % and 5.0% respectively. The clearances were calculated
using the formula U x V/P and I x V/P, respectively. U x V represents the urinary
excretion of  the tracer, I x V represents the infusion rate of the tracer, P represents
the tracer value of the plasma at the end of each clearance period. Errors in the
estimation of GFR due to incomplete bladder emptying and dead space were
corrected by multiplying the clearance of 125I-iothalamate with the formula: clearance
of 131I-hippuran (I x V/P)/clearance of 131 I-hippurate (U x V/P). Filtration fraction was




as the ratio of MAP and ERPF. Urine collection was performed right after blood
samples were taken.
Assay methods
All blood samples were drawn in prechilled tubes and centrifuged at 4 °C.
Plasma was stored at -20 °C until analysis. Tubes for angiotensin II sample collection
contained EDTA, enalaprilat and 1,10-phenantroline to prevent in-vitro formation and
degeneration of angII. Plasma for angII determination was stored at -80 °C. Serum
ACE activity was determined by an HPLC-assisted assay [30]. AngII was determined
by radioimmunoassay (Nicols Institute, the Netherlands).  The cross-reactivity of the
angII antibody with angI is 0.1%.  Plasma renin activity was assessed by the
quantification of generated angI as measured by radioimmunoassay (Rianen
angiotensin I RIA kit). Aldosterone was determined by radioimmunoassay [31]. ACE
genotype was determined by polymerase chain reaction (PCR) as described
previously [32]. To prevent mistyping of heterozygotes, intron specific primers were
used. Blood specimen were collected in EDTA tubes, whereafter DNA could be
extracted from peripheral leucocytes. Genomic DNA was amplified by PCR and the
amplified genes were separated by agarose gel electrophoresis.
Statistical analysis
All data are expressed as mean ± 95% confidence intervals (CI). Baseline
values are expressed as absolute values. The responses to angI and angII are
expressed as % change compared to baseline. For hormonal values, the average of
values at 10.00 AM and 12.00 PM are used as baseline value. The blood pressure
values of 10.00 AM to 12.00 PM (at 15 minute intervals) are used as baseline blood
pressure. The % change in MAP during a given infusion step is analysed as the
average of all MAP values that were measured each 5 minutes during the one hour
infusion period. For renal hemodynamics, the average from the clearance periods
from 10.00-11.00 AM and 11.00-12.00 AM are used as baseline. Differences between
means were compared by Wilcoxon test for paired data (liberal and the low sodium,
within one genotype) and unpaired Mann Whitney non-parametric test (between the
three genotypes separately), as appropriate. The responses to infusion of angI and
angII (% change), between the three genotypes were also compared by ANOVA for
repeated measurements with post-hoc Bonferroni comparison. A two-sided P value of
less than 0.05 was considered significant. 




Baseline characteristics during low and liberal sodium intake are given in
table 1 to 3. Plasma ACE activity was higher in DD subjects on both sodium intakes.
The 24-hour values of sodium and potassium excretion demonstrate a dietary
compliance without significant differences between genotypes. A slightly higher body
weight was found during liberal sodium intake that reached statistical significance in
DD subjects only. Liberal sodium intake suppressed PRA and aldosterone, without
significant differences between the genotypes. In the ID and II genotype, but not in
the DD genotype, angII was significantly suppressed by liberal sodium intake as well.
This was associated with a non-significant reduction in plasma potassium (-0.17 ±
0.31 mmol/l) on liberal sodium in DD subjects, in contrast to a slight increase in ID
(0.25 ± 0.32) and II (0.12 ± 0.40) subjects. The change of plasma potassium to
liberal sodium in DD genotype was significantly different compared to ID and II
genotype (p<0.05)
The absolute values of blood pressure, renal hemodynamics and hormonal
parameters before, during and after (recovery data after two hours at 4.00 PM) angI
infusion are given in table 2 and 3. The % change from baseline are shown in figure
1 and 2. During low sodium intake, the changes from baseline during both doses of
angI were similar for the genotypes, with comparable rises in MAP, ERPF, RVR, angII
and  aldosterone. Also, the reductions in GFR and PRA were similar for the
genotypes. However, during liberal sodium intake a significant difference in response
to angI (8 ng/kg/min) was apparent between the genotypes (all given as % change
± 95% CI). The rise in MAP was significantly higher in DD genotype (P=0.002 by
repeated measures ANOVA), with a mean increase of 22 ± 2 (DD) compared to  13 ±
5 (ID) and 12 ± 6 (II). The renal hemodynamic response to angI was significantly
different with a fall in GFR of 17.9 ± 4.7 (DD) compared to 8.8 ± 3.4 (ID) and 6.4 ±
5.9 (II) (p<0.05), and a mean increase in RVR of 100.1 ± 19.7 (DD) compared to
73.0 ± 16.3 (ID) and 63.2 ± 16.9 (II) (p<0.05). Also, the rise in aldosterone level
during angI infusion in DD genotype was significantly higher with a rise of 650 ± 189
(DD) compared to 343 ± 71 (ID) and 254 ± 99 (II) (p<0.05) (P=<0.0001). In
contrast, the fall in ERPF and PRA and the rise in angII were comparable between the
genotype groups. 
All responses to angII were similar for the genotypes during infusion of angII,




Table 2. Baseline characteristics, response parameters during angI infusion and recovery data during low
sodium diet. Mean ± 95% CI are given.
baseline 4 ng/kg/min 8 ng/kg/min recovery
DD
MAP (mmHg) 90 ± 3 92 ± 4 101 ± 3 89 ± 3
GFR (ml/min/1.73 m2) 121 ± 8 111 ± 10 110 ± 10 122 ± 15
RVR (MAP/ERPF) 0.16 ± 0.02 0.21 ± 0.02 0.28 ± 0.03 0.17 ± 0.02
ERPF (ml/min/1.73 m2) 555 ± 39 439 ± 33 366 ± 39 514 ± 60
PRA (nmol angI/l/hr) 0.64 ± 0.34 0.39 ± 0.27 0.17 ± 0.10 0.44 ± 0.26
AII (pg/ml) 35.6 ± 19.4 57.9 ± 30.3 77.0 ± 28.4 31.5 ± 18.4
Aldosterone (nmol/l) 0.42 ± 0.16 0.99 ± 0.32 1.41 ± 0.45 0.31 ± 0.12
ID
MAP (mmHg) 89 ± 3 93 ± 4 100 ± 4 89 ± 3
GFR (ml/min/1.73 m2) 111 ± 9 105 ± 9 106 ± 9 115 ± 9
RVR (MAP/ERPF) 0.17 ± 0.02 0.21 ± 0.03 0.27 ± 0.03 0.18 ± 0.02
ERPF (ml/min/1.73 m2) 557 ± 68 448 ± 50 383 ± 42 508 ± 52
PRA (nmol angI/l/hr) 0.61 ± 0.18 0.36 ± 0.15 0.25 ± 0.10 0.51 ± 0.16
AII (pg/ml) 53.7 ± 13.8 63.9 ± 13.3 106.2 ± 33.0 34.2 ± 9.9
Aldosterone (nmol/l) 0.50 ± 0.10 1.15 ± 0.21 1.51 ± 0.31 0.26 ± 0.07
II
MAP (mmHg) 87 ± 7 89 ± 9 98 ± 9 84 ± 7
GFR (ml/min/1.73 m2) 109 ± 12 107 ± 11 108 ± 14 115 ± 13
RVR (MAP/ERPF) 0.18 ± 0.02 0.22 ± 0.03 0.28 ± 0.04 0.18 ± 0.02
ERPF (ml/min/1.73 m2) 504 ± 32 407 ± 21 348 ± 28 470 ± 27
PRA (nmol angI/l/hr) 0.49 ± 0.31 0.19 ± 0.08 0.22 ± 0.22 0.43 ± 0.28
AII (pg/ml) 58.0 ± 27.3 70.3 ± 28.2 107.0 ± 48.2 45.4 ± 26.7
Aldosterone (nmol/l) 0.53 ± 0.27 0.94 ± 0.36 1.25 ± 0.40 0.27 ± 0.09
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Table 3. Baseline characteristics, response parameters during angI infusion and recovery data during 
liberal sodium diet. Mean ± 95% CI are given.
baseline 4 ng/kg/min 8 ng/kg/min recovery
DD
MAP (mmHg) 88 ± 2 97 ± 2 107 ± 2 86 ± 4
GFR (ml/min/1.73) m2 125 ± 10 112 ± 12 104 ± 13 123 ± 10
RVR (MAP/ERPF) 0.16 ± 0.01 0.22 ± 0.02 0.32 ± 0.03 0.17 ± 0.02
ERPF (ml/min/1.73 m2) 565 ± 36 433 ± 28 326 ± 34 518 ± 41
PRA (nmol angI/l/hr) 0.21 ± 0.07† 0.09 ± 0.07 0.05 ± 0.04 0.19 ± 0.08
AII (pg/ml) 29.8 ± 15.2 52. 5 ± 20.4 115.4  ± 74.4 30.2 ± 16.0
Aldosterone (nmol/l) 0.17 ± 0.08† 0.52 ± 0.27 0.99 ± 0.31 0.14 ± 0.07
ID
MAP (mmHg) 91 ± 4 98 ± 4 103 ± 4 88 ± 4
GFR (ml/min/1.73) m2 121 ± 10 110 ± 10 110 ± 9 124 ± 10
RVR (MAP/ERPF) 0.17 ± 0.02 0.23 ± 0.04 0.29 ± 0.04 0.17 ± 0.02
ERPF (ml/min/1.73 m2) 591 ± 86 442 ± 66 369 ± 43 536 ± 71
PRA (nmol) angI/l/hr) 0.24 ± 0.07† 0.15 ± 0.06 0.11 ± 0.06 0.24 ± 0.11
AII (pg/ml) 15.4 ± 5.5† 42.1 ± 14.1 76.9 ± 27.4 14.3 ± 4.3
Aldosterone (nmol/l) 0.16 ± 0.03† 0.47 ± 0.10 0.70 ± 0.12 0.13 ± 0.05
II
MAP (mmHg) 92 ± 6 94 ± 6 103 ± 9 88 ± 8
GFR (ml/min/1.73 m2 120 ± 9 112 ± 14 112 ± 13 123 ± 11
RVR (MAP/ERPF) 0.18 ± 0.02 0.23 ± 0.03 0.29 ± 0.04 0.19 ± 0.03
ERPF (ml/min/1.73 m2) 544 ± 32 417 ± 46 364 ± 34 583 ± 40
PRA (nmol angI/l/hr) 0.21 ± 0.09† 0.11 ± 0.06 0.09 ± 0.05 0.21 ± 0.14
AII (pg/ml) 21.9 ± 14.9† 53.9 ± 24.8 101.0 ± 44.4 32.3 ± 17.8
Aldosterone (nmol/l) 0.17 ± 0.07† 0.48 ± 0.21 0.56 ±0.21 0.18 ± 0.10




Figure 1. The responses of MAP, RVR, GFR and ERPF (mean % change ± 95% CI) to infusion of
angI and angII, 4 and 8 ng/kg/min respectively, during low (open bars) and liberal
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Figure 2. The responses of aldosterone, angiotensin II and PRA (mean % change ± 95% CI) to
infusion of angI and angII, 4 and 8 ng/kg/min respectively, during low (open bars) and
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This study is the first to provide data on the effect of ACE genotype on the
renal response to angI in healthy subjects. During liberal sodium, the responses of GFR
and RVR, as well as the responses of blood pressure and aldosterone to angI were
enhanced in the DD genotype. Dietary sodium restriction, studied in the same
individuals, annihilated the differences between the genotypes, suggesting gene-
environment interaction between sodium status and ACE genotype. 
So far, data on ACE genotype and renal hemodynamics were reported only for
diabetic subjects [33,34], Data in early diabetes suggest that ACE genotype may be
relevant to renal hemodynamics [33,34]. As glycemic status however, interacts with the
impact of ACE genotype on renal hemodynamics [35], the signficance of these findings
for non-diabetic subjects is unclear. In our healthy volunteers renal hemodynamic
parameters were not different between the genotypes before angiotensin infusion on
either sodium intake. During liberal sodium, responses of ERPF were not different for
the genotypes, but due to the larger increase in MAP, the rise in RVR was significantly
more pronounced in DD subjects. Remarkably, in spite of the higher blood pressure,
the decrease in GFR was larger as well. This suggests that the difference between the
genotype groups is due to a difference in afferent arteriolar (or mesangial) response to
angI.  
The enhanced response of aldosterone to angI that we found in the DD
subjects during liberal sodium has not been observed before. [21-23, 36]. Previous
studies, however, did not standardize dietary sodium, and the reported 24-hour sodium
excretion was lower than our liberal sodium condition, ranging from 100 to 150
mmol/day. As our data suggest that liberal sodium is a prerequisite for differences in
angI response between the genotypes, the lower sodium intake may partly explain the
discrepancy with our findings. However, previous studies did not standardize potassium
intake (which affects the responsiveness of aldosterone as well [37,38] either, which
hampers a direct comparison with our data. Recent data in heart failure patients,
demonstrating association between DD genotype and aldosterone escape during ACE-
inhibition [39], can be considered in line with our data and point towards possible
clinical relevance of our findings. PRA was expected to be more downregulated in DD
genotype during angI infusion. There was a distinct trend towards such a difference,
PRA being suppressed to approximately half its baseline value in II and ID, but to one-
third of its baseline in DD. However, in our protocol PRA suppression was not a
sensitive parameter to detect differences in angI elicted responses, as PRA values
during angI infusion were near the lower limit of detection in several patients, also in
the II/ID group. This hampers the detection of statistical differences in PRA
downregulation between the genotype groups.
Thus, during liberal sodium, responses to angI of three unrelated parameters,
blood pressure, GFR, and aldosterone, were enhanced in DD subjects. An increased
angI response could reflect enhanced conversion of angI, or increased responsiveness
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to angII. In accord with previous studies we found no differences in angII responses
between the genotypes [21,40,41]. It could be argued that our study-design does not
exclude carry-over from the angI infusion. However, after withdrawal of angI, blood
pressure and renal hemodynamics quickly returned to baseline values and remained
stable during the two-hour washout period. Taken together with previous studies, these
data render it unlikely that differences in angII sensitivity account for the differences in
angI responses. 
As anticipated, plasma ACE levels were highest in DD genotype. It would be
logical to assume that this could account for increased angI responses, by generating
more angII from a given dose angI. However, plasma angII levels during infusion of
angI were similar for the genotypes. Ueda et al. [21,36] and  Brown et al. [42]
reported higher plasma angII during angI infusion in DD subjects, but only during use
of higher doses of angI compared to this study. During infusion of doses comparable to
ours,  the pressor response to angI was enhanced in DD subjects [21,36], without
differences in plasma angII. Apparently, the pressor response to angI can be enhanced
without detectable difference in plasma angII. It as been pointed out, however, that
the value of plasma angII levels as an index of conversion of angI to angII is relatively
limited without an index of angII clearance [43]. 
Increased tissue angI conversion should be considered as well. It is usually
assumed that renin, and not ACE activity, is rate-limiting for the generation of angII.
However, recent data suggest that elevated ACE activity can have pathophysiological
consequences indeed. Transfection of  vascular smooth muscular cells with human
ACE has been shown to result in an increased wall to lumen angII ratio,
demonstrating that overexpression of tissue ACE is associated with biological effects
[44]. Others did similar findings [45]. Also, in humans with myocardial infarction and
increased cardiac ACE expression, not only de novo cardiac angiotensin I production
is increased but the fractional conversion to angII [46]. Other evidence for the
biological relevance of differences in ACE activity was found by a recent study of
Gainer et al [47]. The absence of differences in plasma ACE activity between ACE
genotypes, as found in blacks, was associated with a diminished difference in
vasodilator response to bradykinin between the different ACE genotypes. In contrast,
whites with DD genotype do have a higher ACE activity; in this group the  response
to bradykinin was clearly attenuated in DD subjects.
In man, infusion of equimolar doses of angI and angII elicited similar
responses of MAP and aldosterone, despite lower angII levels during angI infusion,
suggesting that angII formation at tissue level contributes to the response to angI
[48]. In the DD genotype an enhanced vasoconstrictor response to angI was found in
isolated human blood vessels [40] and in forearm blood flow measurements [41], in
the absence of differences in angII response and without significant difference in
plasma angI [41]. These studies suggest that differences in vascular conversion of





Interestingly, the differences in angI responses between the genotypes were
abolished by low sodium. This was found for parameters for which low sodium is
known to blunt the angiotensin response, i.e blood pressure and GFR, as well as for
aldosterone, where low sodium is known to enhance the response to angiotensin. It
could be argued that our study had insufficient power to substantiate the null-finding
during low sodium. However, the observations on low versus liberal sodium were made
in the same individuals, and the confidence intervals of the responses were comparable
on low and liberal sodium. Consequently, the power to detect differences between the
genotypes was similar on both sodium intakes. Taken together with the concordance of
the effect of sodium for three independent parameters, we consider it likely that the
blunting of the differences between the genotypes by low sodium is genuine. We
cannot exclude the possibility, however, that a much larger study could detect small
differences between the genotypes on low sodium.  
The impact of sodium on the phenotype in ACE I/D polymorphism is in line
with our finding in proteinuric patients, in whom a poor response to ACE-inhibition in
DD homozygotes was found only in subjects ingesting excess sodium [24]. Thus, liberal
sodium may be a prerequisite for expression of the unfavourable phenotype not only in
healthy subjects, but also in relevant clinical conditions. In the present study we did not
specifically investigate the mechanism of the interaction of sodium status with
genotype, but some clues can be derived from the litterature. Ueda et al [21, 36] found
a greater pressor response to angI in DD homozygotes ingesting approximately 150
mmol sodium/day. Lachurié [22] on the other hand, found no differences in angI
response in subjects pre-treated with renin-inhibition to eliminate effects of differences
in background RAAS-activity. Taken together with our finding that sodium intake (i.e a
manoeuvre that modifies background RAAS-activity) is a determinant of differences
between the genotypes, this suggests that sodium-dependent differences in
background RAAS-activity are relevant to differences in angI responses between the
genotypes. 
What differences in background RAAS-activity or –function could be involved?
In accord with other studies, pre-infusion values of plasma RAAS hormones were not
different between the genotypes. Yet, comparison of low and liberal sodium suggests
that ACE genotype might exert effect on the response of the RAAS to altered sodium
intake. The shift from low to liberal sodium did not alter plasma angII in the DD
genotype only. If this implicates facilitated generation (or reduced breakdown) of angII
during liberal sodium, or hampered angII generation (or enhanced breakdown) during
low sodium, this would be compatible with enhanced response to angI during liberal,
but not during low sodium intake. This may seem at variance with the lack of a
difference in plasma angII increments during angI infusion, but as noted above
interpretation of plasma angII during angI infusion is difficult. Plasma aldosterone was
adequately suppressed during liberal sodium intake irrespective genotype, which may
seem at variance with the relatively fixed values of plasma angII in  DD subjects.
However, liberal sodium intake elicited a small but significant decrement in plasma
                                              Response to angiotensin I in DD genotype is blunted by low sodium
___________________________________________________________________________
95
potassium in the DD genotype only. As a lower plasma potassium suppresses
aldosterone [37,38] this may have accounted for the adequate net suppression of
aldosterone in DD genotype during liberal sodium, despite inadequate angII
suppression. An effect of genotype on the adaptation to altered sodium intake is
furthermore suggested by the higher body weight during liberal sodium in DD subjects,
suggesting excess sodium retention in these subjects. However, further study, including
assessment of sodium and potassium balance during the shift in sodium intake would
be needed to support these assumptions.
Plasma ACE activity was not affected by sodium status in either genotype.
Whether sodium status could affect tissue ACE activity in man, with possible differences
between genotypes, is unknown. Interestingly, Boddi et al. [49] recently found that
fractional angI conversion in the peripheral vascular bed in man was higher during
liberal than during low sodium intake, which could be of relevance to our findings, but
the impact of ACE genotype was not evaluated in their study. Finally, it is known (and
confirmed by our present data) that low sodium intake blunts the systemic and renal
vascular responsiveness to angiotensin, with a reciprocal increase of adrenal
responsiveness [37]. In view of the opposite effects of sodium intake on hemodynamic
and adrenal sensitivity to angiotensin, it seems unlikely that sodium-induced alterations
in responsiveness to angiotensin account for the effect of low sodium on the
differences between the genotypes, as this was found for hemodynamic and adrenal
responses alike. 
In conclusion, during a sodium intake more or less normal for a western
industrialized society, the responses of  blood pressure and renal function, as well as
aldosterone to a pharmacological dose of exogenous angI were enhanced in the DD
genotype. This suggests that the elevated ACE levels in the DD genotype could have
functional significance under specific conditions.  Dietary sodium restriction blunts the
differences between the genotypes. Further studies would be needed to investigate
whether sodium status also modifies clinical phenotypic characteristics of ACE
genotype, and to see whether sodium restriction can be applied as an intervention
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Chapter 7





One of the main features in chronic renal failure is progressive renal function
loss over the years [1-3]. Much scientific effort has been put in elucidating the
mechanisms of progressive renal function loss in patients with renal disease.
Reduction of high blood pressure and proteinuria are main intermediate targets to
prevent progressive renal failure [2,3]. Unfortunately, not all patients have the same
benefit from these renoprotective measures, even if reduction in blood pressure and
proteinuria appears effective. Therefore, individual factors, such as genetic factors
may be important determinants in outcome of both the natural course of renal
disease and the response to renoprotective therapy.
Recent advances in molecular genetic techniques have provided us tools to
investigate the role of genetic factors in the multifactorial process of progressive renal
failure. The angiotensin-converting enzyme gene insertion/deletion (I/D)
polymorphism is the first genetic polymorphism that received great attention with
respect to renal disease [4-6]. Since the discovery of this polymorphism numerous
studies have been devoted to study the role of ACE I/D gene polymorphism with
respect to the susceptibility for acquiring renal disease, the influence on the natural
course of chronic renal failure and the response to renoprotective strategies.
Unfortunately, many contradictory studies were published on the role of the ACE I/D
polymorphism in renal disease. This has resulted in a cautious attitude towards
studies on this subject among many investigators in the field.
The present thesis aims to provide new data concerning the impact of the
ACE I/D polymorphism on the progression of renal disease and the effect of
renoprotective therapy. We will especially put emphasis on the presently
underemphasized role of gene-environment interactions. Directions will be given to
help the reader to interpret present and future studies on this subject and to provide
suggestions for further studies that are neededin the future. 
Chapter 2
In chapter 2 we provide an overview on the vast amount of data that have
been published on ACE I/D polymorphism and renal disease.  The prevalence of the
D-allele in a population appears to vary between subjects of different ethnic origin. In
Caucasian populations approximately 36% have the DD genotype, 48% the ID
genotype and 16% the II genotype [4,7]. This is in contrast with Asian populations
that have a relatively high frequency of II genotype, up to 40% [4,8,9]. High ACE
activity in DD genotype compared to ID and II genotype has been demonstrated not
only in plasma but also in several tissues, including the heart and kidney [10-12]. The
exact role of the specific insertion/deletion basepair fragment in the regulation of ACE
activity remains to be clarified. The fragment is located on an intron and thus cannot
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affect the expression of mRNA directly. It is hypothesized that the insertion/deletion
fragment is in linkage disequilibrium with a still unknown DNA fragment that acts as a
silencer fragment. In this way ACE I/D polymorphism is a marker to detect the
silencer fragment that possibly inhibits ACE mRNA translation [4,5]. Differences and
discrepancies in literature between studies that investigated populations of different
ethnic origin could be partly explained by a variable relationship between ACE I/D
polymorphism and this silencer fragment. 
Almost all studies have shown that ACE I/D polymorphism is not  associated
with a higher risk to acquire a certain type of renal disease [4,5]. However, in
patients with diabetes the discussion whether the DD genotype imposes a risk to
develop diabetic nephropathy has not ended yet. Several studies showed a relation
between DD genotype and the developement of diabetic nephropathy in type I and
type II diabetes [13-16], but other studies refuted these findings [17,18]. Most
studies evaluated relatively small populations with short follow-up. Pooled data could
not solve this problem as one meta-analysis on 4773 patients found an association
between the D-allele and diabetic nephropathy [19], but two subsequent meta-
analyses only showed a comparable association in Japanese subjects [20,21].
Recently, the first prospective study was published. In 310 patients with type I
diabetes, a clearly increased risk was found for patients with DD genotype to develop
microalbuminuria and also to progress to more advanced stages of the disease [22].
Obviously, it is very difficult to delineate the impact of ACE I/D polymorphism on a
multifactorial disease such as diabetic nephropathy. Most studies have to cope with
the flaws of a post-hoc analysis and the pitfalls in performing association studies. This
is further discussed in the general discussion section. 
Many studies have demonstrated a more progressive renal function decline in
patients with DD genotype and chronic renal failure. This has been demonstrated in
both diabetic [4,5,22-25] and non-diabetic [4,5,26-33] chronic renal failure. Some
studies have disputed this association [34-37]. Unfortunately, the contrasting studies
are hard to compare. Heterogeneity in ethnic background, inaccurate definition of
renal disease phenotype i.e. differences in proteinuria and pre-existing rate of renal
function loss and small sample size all contribute to this problem. Some studies
suggest that DD genotype can have impact on rate of renal function loss but that the
impact of the genotype can be obscured by other, stonger risk factors [38,39].
Possible interactions with other genetic or environmental renal risk factors could also
play a role in discrepancies between studies on the role of ACE genotype rate of renal
function decline in different patient populations. 
  Treatment with ACE-inhibitors has become a main tool in the prevention of
progressive renal failure, especially in patients with overt proteinuria [3,40-42]. The
interindividual variability in the efficacy of ACE-inhibition has been the major drive to
study the role of ACE I/D polymorphism on therapeutic benefit. Disappointingly, it has
not become clear whether DD genotype is associated with a better, equal or worse




discussed for the studies on the natural course of the disease also apply to studies on
therapy response. Environmental factors, such as sodium intake, may have an even
larger impact here, as addressed in chapter 5 and 6 of this thesis. 
An important shortcoming in the currently available scientific explorations on
ACE I/D polymorphism is the paucity of studies on the pathophysiological implications
of the polymorphism. The hypothesis that higher ACE activity in DD genotype results
in higher angiotensin II production is often used to justify the great effort that has
been put in association studies. However, only a few studies tried to test this
hypothesis. Several studies showed an increased pressor response to angiotensin I in
DD genotype [49-51], some also found corresponding higher angiotensin II levels
[49,50]. Not all studies however confirmed these findings [52,53]. Potential
explanations to clarify these discrepancies are further discussed in chapter 6. 
Chapter 3
In the study described in chapter 3 we investigated the impact of ACE I/D
polymorphism on the progression in rate of renal function decline. In a previous study
of our department in 81 patients with chronic renal failure, patients with the DD
genotype had a significant steeper slope of renal function loss compared to patients
with the ID and the II genotype during intervention treatment [33]. Reduction in
blood pressure and proteinuria versus baseline were comparable for all genotype
groups. This suggested that patients with DD genotype were resistant to
renoprotective therapy. To test this hypothesis, in the present study, we assessed the
rate of renal function decline in the same study population before they entered this
intervention trial. In accord with the findings during intervention, patients with the
DD genotype had a more progressive rate of renal function loss over time. However,
the difference in renal function loss between the pre-intervention period and the
intervention period was  far more greater in the DD genotype group as compared to
the ID and the II genotype patients. In ID and II genotype, the improvement in slope
was only modest. Thus, renoprotective benefit in the DD genotype patients was
considerable. This provides evidence that renoprotective therapy in DD patients is
even relatively more effective, which prompts for a different interpretation of our
previous study. Only the absolute effect appears to be insufficient to result in
comparable rates of renal function decline in different genotypes. Another interesting
finding in this study is that the pre-intervention rate of renal function decline
determines the benefit of renoprotective therapy. Patients with a fast renal function
decline showed relatively large improvement in rate of renal function decline,
whereas patients with slow progressive renal failure show only modest (but still
important) improvement. The predictive value of pre-intervention rate of renal
function decline for treatment benefit is of obvious relevance for future studies on
renoprotective intervention, as it indicates that it would be important to consider prior
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rate of renal function loss as a randomization parameter, as randomization on cross-
sectional parameters may not always ensure a good match for risk of renal function
loss. Also, prior rate of renal function loss could help to define the renal phenotype
more accurately in studies on ACE I/D polymorphism and the effect on natural course
of disease and effect of renoprotective strategies. A rapid rate of renal function loss
can identify patients that may particularly benefit from intervention treatment. 
Chapter 4      
In this study we investigated the effect of ACE I/D polymorphism on the
short-term response to ACE-inhibition in 61 patients with proteinuria. A good short-
term response to ACE-inhibition is an important predictor of a favourable long-term
renal outcome [42]. In chapter 3 we demonstrated that patients with DD genotype
have a worse long-term renal prognosis despite treatment with ACE-inhibitors. It was
hypothesized that short-term response to ACE-inhibition was less effective in DD
genotype. However, in this study we demonstrated an equal short-term response to
ACE-inhibition for blood pressure, proteinuria and renal hemodynamic parameters for
all three genotypes. The results of this study can however not be easily translated to
the population studied in chapter 3. Patients from chapter 3 had only modest or no
proteinuria. The patients studied in chapter 4 had far more significant proteinuria but
on the other hand a stable renal function within the time frame of the protocol, which
is in  contrast to the data in the population in chapter 3. The outcome of other
studies that investigated the impact of ACE I/D polymorphism on short-term
antiproteinuric response to ACE-inhibition have been variable [43-48]. Differences in
study protocols, patient characteristics and other exogenous factors are probably
responsible for these differences. This suggests future studies should focus on the
interaction between ACE genotype and other  factors that determine therapy
response.  Also, studies should be sufficiently powered to detect differences in
therapy response, as the number of patients analysed in these studies, including
ours, were limited.   
Chapter 5
In this study we investigated the role of sodium intake on the short-term
effect of blood pressure and proteinuria to ACE-inhibition in relation to ACE I/D
polymorphism. Activation of the RAAS improves the antiproteinuric response to ACE-
inhibition by either sodium restriction or co-treatment with a diuretic [53-54]. In the
present analysis we demonstrated an association between sodium intake and the
short-term renal response in DD genotype. We studied the short-term response of




proteinuria (> 1gr/day) in relation to sodium status as assessed by urinary sodium
excretion. In patients with ID and II genotype this short-term response did not
correlate with sodium intake over a wide range of sodium intakes. In contrast, the
short-term response to ACE-inhibition in DD genotype showed a significant
correlation with urinary sodium excretion. In DD patients with high sodium intake the
responses of both blood pressure and proteinuria were relatively poor. This study is
one of the first to demonstrate the importance of a genetic factor (ACE genotype) in
interaction with an environmental factor (sodium intake). However, as important as
this finding may seem, these results do not directly implicate that response to ACE-
inhibition is sensitive to sodium intake only in patients with the DD genotype. Due to
the post-hoc design of the study, the impact of sodium intake was studied in relation
to inter-individual differences rather than  by prospectively alterering sodium intake
with each patient as his own control. From the point of view of clinical applicability, it
would be of practical use to estimate the benefit of sodium restriction in individual
patients. Therefore, this is the subject of a current study at our department to obtain
this prospective confirmation. Moreover, we sought to establish proof of the principle
for gene-environment interaction between sodium status and ACE genotype in
healthy volunteers, as is described in the next chapter.
Chapter 6
In this chapter we describe our study that aims to prove the hypothesis that
subjects with DD genotype have enhanced angiotensin I conversion to angiotensin II.
We infused both angiotensin I and, after a washout period, also angiotensin II in
healthy subjects to study the response of blood pressure, renal hemodynamics and
hormonal parameters. In order to detect gene-environment interaction with sodium
status, this experiment was performed twice, on two consecutive days after one week
of sodium restriction and liberal sodium intake respectively, in randomized order. In
DD subjects we demonstrated increased response of blood pressure, glomerular
filtration rate and aldosterone secretion to infusion of angiotensin I as compared to
ID and II subjects. Angiotensin II infusion elicited similar responses in the three
genotypes, indicating a similar angiotensin II sensitivity in the three genotypes. This
strongly suggests that the enhanced angiotensin I responses are the result of a
higher ACE activity leading to increased angiotensin II formation. However, we could
not demonstrate a difference in angiotensin II levels. A conclusive explanation for
these findings cannot be given but it is possible that increased conversion to
angiotensin II at tissue level is present. Several other studies also found evidence for
an increased response to angiotensin I in DD genotype [49-51]. Some of them found
higher plasma angiotensin II levels but these used doses of angiotensin I higher than
ours. This could explain the difference with  our findings as increased angiotensin II
levels in DD subjects were only reported in studies were a relatively high dose of
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angiotensin I were used [49,50]. Moreover, these studies already find an increased
blood pressure response to angiotensin I during an angiotensin I dose that was lower
than the dose required to demonstrate a higher angiotensin II plasma level. Thus,
the blood level of angiotensin II does not directly correspond with the pressor effect. 
Most remarkably, the increased response to angiotensin I in DD genotype
was only demonstrated during liberal sodium intake. Sodium restriction completely
abolished the differences between the genotypes, for blood pressure, renal function,
as well as aldosterone. Again this implicates interaction between sodium intake and
ACE I/D polymorphism, but the mechanism remains obscure. Liberal sodium intake
will lead to angiotensin II receptor upregulation, It is possible that only under these
circumstances small differences in local angiotensin II concentrations can become
apparent. In contrast,  downregulated angiotensin II receptor concentration during
sodium restriction could  abolish the impact  of small differences in local angiotensin
II concentration. Sodium intake might also affect local uptake or degradation of
angiotensin II, or influence ACE activity itself. Presently, no  human data are available
to support this hypothesis.
GENERAL DISCUSSION 
New genetic technologies have recently contributed to the unraveling of the
human genome nucleotide sequence and prompted studies of comparative genomic
diversity in the human population across the globe. These studies will not only
provide information on the origins of genetic variation, but also will provide a basis
for understanding the genetic basis for complex diseases and traits. As genotyping
techniques are technically simple and become more widely available, studies on gene
polymorphisms have therefore become increasingly popular as a tool to associate
specific polymorphisms with the occurence or course of disease. Geneticists are
aware of the limitations of investigations based on polymorphisms and call for caution
against abuse of association studies. However, many clinical investigators have
overlooked or misunderstood the wariness of this approach [56]. It is for this reason
that polymorphism association studies are probably used much too extensively
without any in-depth knowledge of its underlying theory. ACE I/D polymorphism is
the first polymorphism that was intensively studied in cardiovascular and renal
disease. As can be anticipated, many problems were encountered in the




ACE I/D gene polymorphism; can we freely associate?
Since the first discovery of ACE I/D polymorphism by Rigat et al [7] and the
first major association study that reported an association between the D-allele and
myocardial infarction [39], an impressive volume of data on this subject has been
published. In the years 1995 and 1996 more than 50.000 individuals were genotyped,
an enormous clinical and scientific effort and also an expensive one [56]. However,
this fascinating wave of studies became to a tide. The striking phrase of Pinto and
van Gilst adequately states the current status of ACE I/D polymorphism; “ after a
Good start, conflicting results gave the genotype a Bad reputation, and the stage now
looks rather Ugly ” [57]. Thus, it seems that ACE I/D polymorphism is a victim of its
own success. As more novel or discrepant associations are published, the less likely it
will be that a unifying conclusion on the role of ACE I/D polymorphism will become
available. What went wrong in our approach? The explanation can be twofold; first,
association studies have not always been conducted according to currently available
standards. Second, almost shameful little attention has been paid to the pathogenetic
mechanisms that may link ACE I/D polymorphism and disease.
What are the conditions for a good association study?
In order to adequately interpret association studies on ACE I/D polymorphism
we must first understand the problems of such studies and define criteria for valid
studies.  First, a disease locus should be identified. Common inherited disease or risk
factors are however difficult to study as a combination of various genes and different
environmental factors are often involved. Complex diseases are often thought to be
inherited as they tend to run in families, but they do not show mendelian pedigree
patterns of inheritance. These non-mendelian diseases  may depend on more than
one susceptibility locus, with a variable contribution and interaction of environmental
factors. The identification of such loci can be pursued by different strategies. Studies
in families, either by segregation analysis or by linkage analysis to candidate genes or
markers can be used to localize a gene. This could be followed by positional cloning
and in the general population by association studies in homogeneous populations.
However, segregation analyses are prone to bias. In case of linkage analysis studies,
a precise genetic model including disease frequency and the penetrance of each
genotype are needed. Thus, population association studies are mostly used for the
detection of susceptible loci. In association studies we test whether a genetic marker
occurs more frequently in cases than in controls. If so, the polymorphism is either the
susceptibility locus itself, or in linkage disequilibrium with this locus. In both cases the
polymorphism should identify people at risk to develop disease or to develop
complications such as progressive renal failure in pre-existing renal disease. 
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Several confounding factors have been recognised in this type of study. First,
the definition of the phenotype for cases and controls is often variable due to
different definitions and also to the heterogeneity of the disease phenotype. Second,
genetic background of the cases and controls are often mixed, especially in
multicultural areas. This phenomenon elicits the risk of so-called population
admixture, which can cause erroneous association if a study includes genetically
distinct subpopulations. Some ethnic subpopulations can  coincidentally display both a
higher frequency of disease and certain allelic variants. Thus, in this case a biologic
effect of the genetic variant itself is not present. In view of differences in genetic
background it is interesting to note that most studies that found positive association
between the D-allele and cardiovascular disease and risks are of European origin.
Large sample studies from the US often failed to demonstrate an association.
However, the increase in circulating ACE activity in the DD genotype is a consistent
finding in European study populations, in contrast to US study populations for which
such data are lacking [57]. In support with this assumption it was found that the
correlation between ACE activity and the D-allele was not present in an population of
afro-american origin, a substantial part of the population in US study samples [58]. It
is feasible that the ACE I/D polymorphism has lost its linkage to the functional gene
in subjects of afro-american origin. The heterogeneous background of this population
may therefore explain the less increased risk of this ancestral gene variation in
contrast to a population with low migration rate. Thus, only in homogeneous
populations correlations can be found, the so-called founder effect. This loss of the
hypothesized linkage with the unknown functional DNA fragment was first
hypothesized to be due to the moderate physical distance between the ACE I/D
polymorphism locus and this functional DNA fragment. However, also the different
frequencies of the genotypes in the different subpopulations [4], genetic mixture due
to cultural diversity within one population and also the age (time of origin in a
phylogenetic sense) of the allelic variant can determine loss of linkage in certain
populations [59]. In conclusion, if positive study results  are not replicated in different
populations, this  could lead to a  rejection of a true association recorded in a specific
population. Third, methodological difficulties play a role. Studies should have
adequate genotyping methods and use appropriate statistical methods with sufficient
power and prefarably low P values. Fourth, publication bias is a major concern as
studies that find a positive association are preferentially published, leading to an
overestimate of the significance of a specific polymorphism. In conclusion,
considering all these problems, we are in urgent need to define a limited and
generally accepted set of methods and criteria that allow appropriate assessment of
association studies in the future and help with the comparison of individual study
results. We should however not be discouraged by these problems as our standards
will evolve as knowledge improves on complex traits and on appropriate strategies for




ACE gene I/D polymorphism; does it have functional consequences? 
As mentioned earlier, we first need to answer basic pathophysiological
questions to be able to understand the impact of ACE I/D polymorphism in renal
disease. The question is whether there is a plausible credibility that ACE DD genotype
is associated with increased risk for progressive renal failure or difference in response
to renoprotective therapy.  In other words, does it makes biological sense that the D-
allele affects the gene product in an meaningful way? Before discussing the current
concept and knowledge we have on the pathophysiological consequences of ACE I/D
gene polymorphism, we should first realize that the relatively high ACE activity in DD
genotype is the central concept in our current running hypothesis on its deleterious
effects in cardiovascular and renal disease. Although the I/D locus is in strong
disequilibrium with the elevated ACE levels in many cases, recent data showed that
ACE I/D polymorphism is not always a clear determinant of ACE activity. The
discrepant results in populations of different ethnic origin already pointed forward to
recent observations that the level of linkage disequilibrium can vary. Indeed, the I/D
locus is strongly linked to ACE activity in Caucascian subjects but recent genetic
studies found no association in afro-american and afro-caribbean subjects [58,60].
Differences in ACE activity between populations of variable ethnic origin also
appeared to be functionally relevant [61]. Absence of differences in plasma ACE
activity between ACE genotypes, as found in blacks, results in a diminished difference
in vasodilator response to bradykinin between ACE genotypes. In contrast, in whites
with DD genotype, the higher ACE activity was accompanied by a clearly attenuated
response to bradykinin, with remarkable differences compared to white ID and II
genotype subjects. Perhaps this finding  may even have therapeutical implications in
understanding the observed ethnic variation in the effect of antihypertensive efficacy
of ACE-inhibition. We are therefore in great need to identify polymorphic DNA
fragments that are more closely associated with ACE transcription. Two studies aimed
to track down such alternative polymorphisms on the ACE gene [60, 62]. In these
studies, it was shown that the I/D locus is in linkage disequilibrium with ACE activity
in Caucasian subjects but not in Afro-Caribbean subjects. Two single-nucleotide
polymorphic sites were identified that were in strong linkage disequilibrium in both
populations [60], as another study found a comparable third locus [62]. This major
breakthrough is an important step to determine where the quantitative trait locus
that determines ACE level itself is excactly positioned. In the near future we may be
able to use more different polymorphisms of the ACE gene to identify patients at risk
for progressive renal disease or therapy resistance.
At present, we use DD genotype and the accompanying higher ACE activity,
as  found in Caucasian subjects, as the central component in our pathophysiological
concept. The mechanisms by which this variability in ACE level is caused were not
precisely defined after the first report of Rigat et al [10]. Subsequent studies showed
that ACE activity was also elevated in tissue [11,12]. This suggested that on a
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DNA/mRNA level ACE expression was variable in ACE I/D polymorphism. This
hypothesis was confirmed in two studies on ACE mRNA level in human left ventricular
tissue which demonstrated increased expression of ACE mRNA in DD genotype
patients with heart failure [63,64]. However, these differences are not uniformly
present  in all tissues as similar ACE mRNA expression was found in human atria
[65,66]. Thus, regulation of gene expression appears to be cell or tissue specific. In
the current concept of increased angiotensin I conversion in the kidney and the
hypothesized repercussions on renal disease, the findings of Mizuiri et al are
important  [67]. In their recent study it was first demonstrated that increased ACE
mRNA level expression in human renal tissue is present in DD genotype with a 3- to 6
fold higher ACE transcripts compared to ID and II genotype respectively.
As a physiological basis for the difference in plasma and tissue ACE (including
the kidney) was recently demonstrated, the next point of discussion is whether high
ACE activity has functional consequences and leads to increased conversion of
angiotensin I. The enzymatic activity (KM) of ACE was shown not to be affected by
ACE genotype [68]. Thus, high ACE activity itself must be responsible for increased
angiotensin I conversion. However, it is usually assumed that renin is rate-limiting for
the generation of angiotensin II. At regional (tissue) level, membrane-bound ACE is
responsible for conversion of angiotensin I [69]. This process follows a first-order
kinetics, since angiotensin I levels are approximately six orders of magnitude below
the KM for angiotensin I [70,71]. This will even apply at angiotensin levels that are
10.000-fold higer than normal. In accord with these findings, conversion to
angiotensin II was found to be similar over a wide range of arterial angiotensin I
levels, in both animal and human studies [ 69,72,73]. Angiotensin I-induced blood
pressure responses in rats of two strains with low and high ACE activity, was shown
to be similar despite a two to three fold difference in ACE activity [74]. Transgenic
rats that have a 40-fold ACE overexpression also had a normal angiotensin II level
[75]. On the other hand, there is contradictory evidence that variable ACE expression
and activity can determine angiotensin II formation to some extent. Increased local
angiotensin II production in response to increased ACE expression was shown both
for infused and locally formed angiotensin I in two experimental models [76,77].
Because of these contradictory data, the hypothesis of increased formation of
angiotensin II in humans with DD genotype is highly controversial. Unfortunately,
only limited data from human studies are available. In humans with  increased ACE
expression during an episode of unstable angina, not only de novo angiotensin I
production was found to be increased but also the fractional conversion to
angiotensin II [78]. In contrast, regional angiotensin I to II conversion in the human
forearm and leg did not parallel the previously described DD genotype related
differences in ACE activity [79]. This is in accordance with two previous studies that
studied the blood pressure response to angiotensin I in healthy volunteers [52,53],
although these studies did not investigate regional conversion rates. Ueda et al




angiotensin I in DD genotype [49,50]. In both studies angiotensin II levels were
significantly higher during angiotensin I infusion, but only during high dose
angiotensin I administration. In our own study described in chapter 6, we report
comparable findings, but differences in angiotensin II levels were not observed,
possibly because the dose of angiotensin I was not as high as in the studies of Ueda
et al. [49,50]. 
Not only at the level of angiotensin II formation but also at the level of
aldosterone secretion, recent data on ACE I/D polymorphism became available. Our
findings are in line with an experimental study of Ueda et al. who studied the effect
of an acute dose of ACE-inhibition in healthy subjects with different ACE genotypes
[50]. In subjects with DD genotype, after the drug induced initial fall, the rise in
angiotensin II plasma levels occurred significantly earlier as compared to subjects
with ID and II genotype.  Thus, even during ACE-inhibition, a higher ACE activity in
DD genotype results in apparent differences in RAAS parameters. This findings
strongly suggests the importance of ACE I/D polymorphism in terms of therapy
response. This could be in line with our own data on facilitated aldosterone
stimulation discussed in chapter 6. With regard to clinical relevance, this finding
seems important as higher aldosterone levels are important in the process of
myocardial and vascular fibrosis [80]. Also, inhibition of aldosterone action by
spironolactone is associated with reduced risk in morbidity and death in patients with
heart failure [81]. A recent study in heart failure patients revealed that DD genotype
was associated with aldosterone escape during ACE-inhibition [82]. Thus, increased
aldosterone production or and escape in a therapeutical setting could be a
mechanism that is involved in increased cardiovascular risk in DD genotype.
Unfortunately, there are no data on possible deleterious effects of aldosterone in
human renal disease. 
Feedback regulaton in the RAAS should also be considered. If increased
angiotensin I conversion will result in higher  angiotensin II levels,  a negative
feedback loop via a decrease in renin release should compensate for this effect. Such
a mechanism could therefore reduce the rate of angiotensin II generation to normal
levels in steady state conditions. A large epidemiological study showed that the
downregulation of renin, prorenin and aldosterone was not significantly different
between the three  genotypes [83]. In our own study discussed in chapter 6, a
distinct trend of higher PRA suppression in DD genotype during angiotensin I infusion
was found, but due to the very low levels of PRA this study was not sufficiently
powered to resolve this question. Barlassina et al. studied 145 non-treated
hypertensive subjects in a sodium-repleted state [84]. A significantly lower PRA level
in DD subjects as compared to II genotype was detected, with intermediate levels (as
expected by the current hypothesis) in heterozygotes. 
In this respect, it would be very interesting to investigate the presence of
feedback within the RAAS system in tissue. In mice, having one, two or three copies
of the “Ace” gene (ACE gene in rodents), a linear relationship was found between
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ACE activity in serum and the number of gene copies [85]. As a result of apparent
negative feedback, kidney renin mRNA was reciprocally more downregulated in mice
with more Ace copies. This indicates the presence of negative feedback at tissue
level. This  probably explains why blood pressure was similar in all groups. However,
despite this negative feedback, a higher Ace activity seems to be of functional
significance as the pressor response to angiotensin I and the depressor response to
bradykinin were clearly attenuated in the group with reduced Ace gene function in
contrast to the group with increased Ace gene function [86]. However, this was
found in an experimental and pharmacological setting. Thus, the functional
consequences at tissue level  can not be extrapolated from such data. Kidney and
heart weights were found similar between mice with a different number of Ace copies
[85]. Remarkably, renal tubulointerstitial volume decreased significantly with
increasing Ace copy number. Pinto et al. found no increased angiotensin II in heart
tissue in a trangenic model resulting in a 40-fold higher ACE  expression in the
hearts, but nevertheless found more fibrosis in this group [75]. Thus, in models with
high ACE activity, despite negative feedback at tissue renin mRNA level, high ACE
appears to have effects at tissue level. This clearly illustrates that we should not just
focus on hormonal plasma and tissue levels alone but also on structural changes
when formulating a hypothesis that explains the impact of AC I/D polymorphism in
renal disease. 
In summary, there are data indicating that high ACE activity is associated
with increased angiotensin II formation and also with increased aldosterone
secretion. The data are however inconsistent. First, we should be aware that in these
experimental animal studies, a direct comparison and extrapolation to humans must
be made with caution, as marked species differences for the vascular angiotensin II
forming pathways can be present between humans and rodents. The scarcely
available and contradictory data  of clinical studies point out that we still must further
explore the clinical relevance of ACE I/D polymorphism. Until now, apart from studies
of the association type, most studies have focused on experimental and
pharmacological study designs. Angiotensin II and also aldosterone have however
many effects on a structural-tissue  level. Therefore, secondly, we must also focus on
this issue, as it is already known that chronic effects on vascular or cardiac tissue
may precipitate even when differences in plasma are minute and barely detectable
[87].  Finally, we should not forget that conversion of angiotensin I to angiotensin II
is not the only action of ACE. ACE degrades a wide variety of substrates including
bradykinin, substance P and the hemopoietic stemcell regulator AcSDKP. In addition,





Is there evidence for gene-gene interaction?
We can conclude that after a large number of confusing data from
association studies, a number of pathophysiological studies has been performed that
may allow to discern the functional role of of ACE I/D polymorphism. It is clear that
we still do not have all the answers as there are still contradictory results. What can
be the cause of that? First, we have to consider the potential interaction with other
relevant genetic factors. As was explained earlier, we should keep in mind that
whenever an association is found between a genetic polymorphisms and a
phenotype, the possibility that  another gene polymorphism in close proximity to the
one studied is the real causal gene cannot be excluded. The demonstration of
synergistic or interactive effects of two or more genes on different chromosomes,
preferably both with a plausible role in causing the phenotype, would not only
strongly reinforce the likelyhood of their pathophysiological involvement, but also
help us to understand the complexity of the genetic architecture. Some studies have
been addressing the effect of other genetic polymorphisms of the RAAS, such as the
angiotensinogen (AGT) M235T gene polymorphism and the angiotensin II type I
receptor A1166C gene polymorphism [4]. The angiotensin II type I receptor A1166C
gene polymorphism appeared to be associated with an increased response to
angiotensin II in isolated human arteries [88]. A subsequent study investigated the
increased risk for ischaemic cardiac events in relation to combined RAAS
polymorphisms and found interaction between ACE DD genotype and AT(1)R-CC
genotype [89]. As to renal diseases, Pei et al. correlated rapid progression of renal
function loss in IgA nephropathy in patients with the AGT T allele irrespective of ACE
genotype, while AGT MM homozygotes had rapid progression only when DD genotype
was present concomitantly [35]. Severity of renal involvement in diabetic subjects
with the AGT MM to TT genotype was increased in patients also having DD genotype
[90], but interaction was not confirmed in a patients with polycystic kidney disease
[32]. Not suprisingly, these association studies were also hampered by problems of
methodological origin, as discussed previously. This is complicated by the fact that
the genetics of the RAAS are much more diverse than just one or two polymorphism
for each component. With respect to the ACE gene, more than 78 polymorphisms
have been described, with a similar diversity as to the other components [91]. Also,
the RAAS not only has multiple components and genes that define its activity but,
non-RAAS systems can also enhance or counteract this system. Just as one example
of interacting non-RAAS systems, it was shown that vascular contraction was more
dependent  of nitric oxide in vascular rings of DD genotype subjects [51].
Interestingly, in a subanalysis of our data from chapter 6, we found that during high
sodium intake, plasma nitric oxide availability was lower in DD genotype as compared
to the ID and II subjects. During low sodium intake, plasma nitric oxide levels were
comparable [92]. To give an example of other genetic polymorphisms, Barlassina and
coworkers have recently shown that, with an appropriate hypothesis and
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experimental setup, it is feasible to recognize interacting genes in a more logical
sense [84]. A potential interaction between ACE I/D polymorphism and the α-
adducin gene polymorphism was studied in 145 non-treated hypertensive subjects on
a liberal sodium diet. This interaction was hypothesized from the assumed functions
of the genes. An increased angiotensin II level, as hypothesized in DD genotype, is
known to reduce the steepness of slope of pressure-natriuresis relationship, causing
salt-sensitivity. Adducin is a cytoskeleton protein with different isoforms, differentially
affecting sodium-potassium pump activity on the basolateral tubular membrane,
which is the driven force of overall tubular Na+ reabsorption. Hypertensive patients
with the 460Trp genotype of the α- adducin gene  are salt-sensitive, and have a
steeper pressure natriuresis relationship and increased tubular reabsorption [93-95].
The interactive effects of the two polymorphisms were examined by studying the
pressor response to a saline load. It was hypothesized that the degree of suppression
of tissue angiotensin II under saline (RAAS suppression) conditions in DD genotype
would be less effective than in ID/II genotype, and that this functional characteristic
might be enhanced by the presence of the α- adducin 460Trp allele. When analysed
for the two genes separately, the pressor response to saline was not significantly
affected by the DD genotype, as it was in the the α- adducin 460Trp allele group.
However, statistical analysis showed that the two genotypes interacted epistatically in
the pressor response to saline loading, providing evidence for a causal interaction.
This is one of the first elegant examples of the functional consequences of gene-gene
interaction in gene polymorphism research demonstrating the potential of hypothesis-
driven studies with a solid pathophysiological basis. It is clear that without prior
knowledge of the potential role of these interacting genes, it will be extremely
difficult to prove that a certain interaction is present for a given phenotype (risk or
therapy response). In the near future, we should therefore focus on potential gene-
gene interaction, not only in fundamental pathophysiological studies, but also in
studies on disease outcome and response to therapy. If we make this effort, this will
allow us to determine which  polymorphisms act synergistically or on the other hand
compensate for the individual impact of other polymorphisms, which is crucial for
their clinical significance. 
Is there evidence for gene-environment interaction?
It is well-known that the setpoint of the RAAS is modified by several
exogenous factors. Sodium intake, age, gender and disease state can all modify RAAS
activity. In this thesis special emphasis was laid on sodium intake. Sodium restriction
activates the RAAS, which has several therapeutic implications.  In chapter 5 we
described a cross-sectional study that suggested that in DD genotype patients with




sodium intake  as compared to patients with ID and II genotype. In chapter 6 we
found that the response to angiotensin I infusion was enhanced in DD genotype
subjects on a liberal sodium intake. This effect was abolished by adherence to sodium
restriction. This finding indicates that sodium intake should be taken into account in
future studies on ACE I/D polymorphism, both in clinical or also fundamental
pathophysiological studies. 
The mechanisms that explain the impact of sodium intake are not
thouroughly explored. We could speculate that sodium intake influences ACE activity
itself and thus has greater impact on DD genotype. It was recently found that high
salt intake increased not only blood pressure but also ACE expression in the
hypothalamus in Dahl S rats [96]. Dietary sodium loading also stimulated ACE
expression in left ventricular tissue in SHRSP rats [97]. In human subjects it was
found that fractional angiotensin I conversion in the peripheral vascular bed was higher
during liberal sodium intake as compared to low sodium intake [98]. This could be in
line with our findings described in chapter 6. Unfortunately, the impact of variable
sodium intake on ACE genotype, in specific relation with plasma or tissue ACE activity
have not yet been subject of study. The discrepancies in the many studies on ACE I/D
polymorphism could be partly explained by differences in sodium intake, but this is hard
to prove in most studies, as they are not standardized to sodium intake. It is interesting
to review the sodium intake in studies that investigated the angiotensin I to angiotensin
II conversion. The previously discussed positive studies on bradykinin response and
angiotensin I infusion [49,61], as well as the study on synergistic effect of adducin [84]
were all performed in sodium repleted subjects. In two negative studies sodium intake
was not protocollized [52,53]. Lachurié et al. blocked the RAAS by renin-inhibition [52]
but it is not known how this maneuver affects tissue ACE level. In view of the
contrasting effect of sodium intake on tissue and circulating RAAS, Danser et al. found
no evidence for increased angiotensin II formation in human DD genotype subjects but
in many patients the RAAS was activated by the use of diuretics which could have
obscured these results [79].
Another important exogenous factor that has to be considered is blockade of
the RAAS by ACE-inhibition. In many clinical studies patients have used ACE-
inhibition. For several reasons it is very difficult to determine the differences in effects
for different genotypes, especiallly if ACE-inhibitors are not standardized by dose,
type or duration of therapy. It was demonstrated that the percentage of pre-
treatment ACE activity that is blocked is similar for all the three genotype groups
given a fixed ACE-inhibitor dose [50]. However, the absolute residual degree of ACE
activity is variable with higher ACE activity in DD genotype after the acute effect of
intravenously administered ACE-inhibitor weans off [50,99]. One hour after the
administration of an ACE-inhibitior, the rise of plasma angiotensin II during
angiotensin I infusion was prevented in both II and DD genotype. After ten hours
however, plasma angiotensin II levels increased during repeated angiotensin I
infusion only in DD subjects, indicating that after this time period the inhibition of
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ACE had weaned only in DD genotype. Also, long-term blockade of  the RAAS usually
results in an upregulation of several RAAS components by strong feedback
mechanisms. It is currently not known whether RAAS upregulation caused by
institution of ACE-inhibition is genotype dependent. If so, we should take this into
account in the interpretation of studies where ACE I/D polymorphism is studied in
relation with therapeutic efficacy. 
Patient characteristics should also be considered. First,  as discussed earlier,
risk factors with strong impact, such as hypertension or proteinuria, can obscure the
effect of a  risk factor of lesser strengh. Also, the overall clinical condition in subjects
can play a role. The relative risk reduction in subjects with an overall worse prognosis
or progressive course of disease will likely be of clinical relevance, as we also found in
our study described in chapter 5. In adriamycin nephrotic rats, more renal damage is
associated with a higher renal ACE activity, with concomitant worse response to ACE-
inhibition or angiotensin II blockade [100]. Baseline ACE activity is also found to be
higher in diabetic subjects, even in normotensive and normoalbuminuric subjects
[101]. Thus, we should also consider differences in baseline severity of disease and
other relevant disease conditions, such as diabetes, as well. Finally, we should not
forget to pay attention to the gender of subjects included in studies. In sodium-
repleted women, glomerular filtration rate decline to angiotensin II infusion is more
pronounced, but decrease in renal plasma flow was more blunted as compared to
men [102]. Aldosterone baseline levels were lower in women compared to men. This
indicates gender specific differences in the RAAS. Only limited clinical data are
available. Recently, females with chronic renal failure appeared to be at lower risk to
develop end stage renal disease as compared to men [103]. In this study, ACE-
inhibition was uniformly renoprotective in women regardless of their ACE genotype.
However, male subjects only showed beneficial effects in DD subjects. Unfortunately,
data on pre-existing renal failure, described in chapter 3, were not available.
Nevertheless, it is clear that gender is an important confounder in studies on RAAS
disparities and ACE I/D gene polymorphism. 
Conclusions
The clinical genetics of complex diseases is a young discipline. ACE I/D gene
polymorphism was the first polymorphism that has been thoroughly studied in
cardiovascular and renal disease. The many studies in the beginning were fashionable
and got great attention, but we have now come to a point that we have to move
further to discern the role of genetic polymorphisms in general and ACE I/D gene
polymorphism in particular in clinical medicine. However, we shall make little
headway if we do not answer the basic questions on  pathophysiological significance
of the genetic polymorphisms, with special emphasis on the presence of gene-gene




translate this knowledge into clinical benefit. Despite the major efforts, this path is
still poorly lit. With the increasing knowledge on molecular genetics we will be able to
create a cataloque of common-coding-sequence variants in human genes and test
directly for association with a phenotype. With a genome-wide map of known
polymorphisms we can explore the genome for marker-disease association. After a
burst of association studies it is very promising that more recently, new data became
available on the functional impact of ACE I/D polymorphism. If we continue this
effort, determination of ACE genotype in an individual patient might be helpful in the
future, to identify patients at risk for progressive renal disease and also to develop
specific treatment strategies to modify the course of disease. 
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De nieren zijn belangrijke organen voor ons lichaam. De belangrijkste
functies van de nieren zijn het verwijderen van afvalstoffen, het regelen van de
vochthuishouding en de bloeddrukregulatie. In de loop der jaren gaat onze
nierfunctie heel geleidelijk achteruit. In feite is dit te vergelijken met het algemene
ouderdomsproces. Gelukkig hebben de nieren veel reserve. Dit betekent dat bij ieder
mens tot op hoge leeftijd voldoende nierfunctie overblijft. Bij verschillende nierziekten
komt het echter voor dat de nieren schade oplopen met als gevolg een minder goede
nierfunctie. Bij deze patiënten  gaat de nierfunctie per jaar vaak sneller achteruit dan
bij mensen zonder een nierziekte. Als de nierfunctie te slecht wordt geeft dit klachten
en complicaties. Soms wordt daardoor uiteindelijk nierfunctievervangende therapie
noodzakelijk, zoals haemodialyse of buikspoeling. De laatste jaren is veel onderzoek
verricht naar de risicofactoren die de achteruitgang van de nierfunctie beïnvloeden.
De belangrijkste risicofactoren blijken hoge bloeddruk en de aanwezigheid van
eiwitlekkage in de urine (proteinurie). Deze risicofactoren zijn tegenwoordig vaak
goed te behandelen met medicijnen. Ondanks deze betere behandelingsmethoden
blijft nierfunctieverlies een belangrijk probleem. Ook tijdens behandeling zijn
verschillen in snelheid van achteruitgang in nierfunctie tussen patiënten vrij groot,
ook al hebben ze dezelfde nierziekte en worden ze ook op dezelfde manier
behandeld. Deze interindividuele verschillen suggereren dat er nog andere
onbekende, patientgebonden factoren een rol spelen. Één van de gedachten is dat
erfelijke factoren voor een deel de snelheid van nierfunctieverlies bepalen.
GENETISCHE POLYMORFISMEN 
Het idee dat erfelijke factoren een rol spelen bij nierziekten is niet nieuw. Al
heel lang is bekend dat het krijgen van bepaalde nierziekten, zoals bijvoorbeeld
cystenieren, erfelijk bepaald is. In families waarin dit voorkomt bestaat er een
verandering in het erfelijk materiaal, een zogenaamde mutatie, die de ziekte van
generatie tot generatie overdraagt. Een enkele verandering in het genetisch materiaal
heeft dus bij deze mensen grote gevolgen voor de gezondheid. Of erfelijke factoren
ook belangrijk zijn bij het beloop van een, door andere oorzaak ontstane al
aanwezige nierziekte, is veel minder goed bekend. Hoewel familiaire factoren wel een
zekere rol lijken te spelen bij het beloop van nierschade, zijn er geen mutaties
bekend met een vergelijkbaar sterk effect als in het bovengenoemde voorbeeld van
cystenieren. Daarom wordt gezocht naar genetische factoren met subtielere effecten.
Mogelijk spelen meerdere genetische factoren gezamenlijk, al dan niet in interactie
met omgevingsfactoren,  een rol.
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Er is op dit moment veel interesse voor de zogenaamde genetische
polymorfismen. Dit begrip vraagt om enige uitleg. Elke kernhoudende cel van het
lichaam bestaat voor een deel uit zogenaamd DNA. In dit DNA liggen alle
eigenschappen van het lichaam opgeslagen. Het functioneren van elke lichaamscel
wordt gestuurd door dit DNA. Tijdens de celvermenigvuldiging wordt steeds DNA
gekopiëerd. Bij dit proces ontstaan soms veranderingen in het DNA. Dit veranderde
DNA veroorzaakt  soms een andere celfunctie en kan zelfs aanleiding geven tot het
overlijden van een individu (vaak al voor de geboorte) of het krijgen van een ziekte.
Een dergelijke verandering in het DNA wordt ook wel mutatie genoemd. Veel van
dergelijke mutaties worden niet verder overgedragen aan de volgende generatie
omdat ze aanleiding geven tot overlijden of een ernstige ziekte. Het blijkt echter dat
er ook veranderingen in het DNA voorkomen die niet direct grote consequenties
hebben voor het lichaam. Het individu kan dan ogenschijnlijk ongestoord verder
leven. Deze veranderingen blijken enorm vaak in het DNA van de mens voor te
komen en zorgen dus voor een enorme variatie tussen de verschillende individuen.
Een bekend voorbeeld voor een dergelijk “polymorfisme” is het ABO
bloedgroepsysteem. Ieder individu heeft één soort bloedgroep bijvoorbeeld A, maar
in de gehele bevolking bestaan vier soorten bloedgroepen, namelijk A, B, O of AB. De
laatste jaren zijn steeds meer genetische polymorfismen ontdekt. Veel onderzoek is
gedaan om te kijken of bepaalde polymorfismen ook een relatie hebben met het
ontstaan of het beloop van  bepaalde ziekten.
HET ACE POLYMORFISME
In 1991 onderzocht een Franse onderzoeksgroep een gen (een stukje DNA)
dat de informatie draagt van het zogenaamde ACE ofwel angiotensine converting
enzym. Dit enzym speelt een belangrijke rol in het zogenaamde RAAS ofwel renine-
angiotensine aldosteron systeem. In figuur 1 is een vereenvoudigd plaatje van dit
systeem te zien. Het RAAS  speelt een belangrijke rol in de regulatie van de
bloeddruk en de water- en zouthuishouding door de nier. Vanuit de nieren wordt een
signaal afgegeven via de stof renine. Deze stimuleert de vorming van de stof
angiotensine-1. De stof ACE is een enzym dat zorgt dat angiotensine-1 wordt
omgezet in de stof angiotensine-2. Angiotensine-2 is de actieve stof van het RAAS en
regelt onder andere de doorbloeding van de nieren. Angiotensine-2 voorkomt ook dat
het lichaam teveel vocht en zout verliest, via de stimulatie van het hormoon
aldosteron. Tevens lijkt angiotensine-2 betrokken te zijn bij de groei en reparatie van
weefsels. Teveel angiotensine-2 kan echter de doorbloeding van de nieren ongunstig
beïnvloeden, wat bij beschadigde nieren kan bijdragen aan proteinurie. Ook speelt
angiotensine-2 mogelijk een rol bij teveel littekenvorming in de nier nadat er schade





De Franse onderzoekers ontdekten dat er een genetisch polymorfisme bestond voor
het gen dat de informatie draagt voor het ACE. Er bleek sprake van een zogenaamd
insertie/deletie polymorfisme. Dit betekent dat er op een bepaald stuk DNA een extra
stukje wel (dit heet insertie, afgekort I) of niet (dit heet deletie, afgekort D) aanwezig
is. Omdat elke stukje DNA tweemaal in het lichaam voorkomt ontstaan er drie
variaties (genotypen) namelijk II, ID en DD. Elk mens heeft één van de drie
genotypen. Een interessante bevinding is dat het genotype gerelateerd leek met de
hoeveelheid ACE in het bloed. Mensen met het DD genotype hebben gemiddeld het
meeste ACE, mensen met het II genotype het minst. Mensen met het ID genotype
zaten daar precies tussenin. Toen dit bekend was is men gaan onderzoeken wat de
consequenties waren van de verschillen in ACE activiteit. De veronderstelling was, dat
meer ACE leidt tot toename van de angiotensine-2 produktie. Teveel angiotensine-2
zou bij patiënten met een nierziekte en het DD genotype kunnen leiden tot een
snellere achteruitgang van de nierfunctie. De Afdeling Nefrologie van het Acdemisch
Ziekenhuis Groningen vond in een eerder onderzoek inderdaad aanwijzingen voor een
relatie tussen het DD genotype en snel progressief nierfunctieverlies. De vraag was of
deze bevinding puur toeval was of dat er werkelijk een oorzakelijke relatie (een
causaal verband) bestaat tussen het DD genotype en snelle achteruitgang van
nierfunctie. De bovenstaande  bevindingen zijn dan ook aanleiding geweest voor het
huidige onderzoek beschreven in dit proefschrift. Hierbij hebben we ons gericht op de
consequenties voor de behandeling van patiënten met een chronische nierziekte (dit
is immers van praktisch belang) en op meer basaal onderzoek om de mechanismen,
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DOEL VAN HET ONDERZOEK
In het onderzoek beschreven in dit proefschrift wordt de relatie bestudeerd
tussen het ACE polymorfisme en verschillende aspecten van nierziekten. De eerste
vraag die wordt beantwoord is of de relatie tussen het DD genotype en de snelheid
van  nierfunctieverlies, wordt verklaard door een effect op de werkzaamheid van de
gebruikelijke therapie. Met name wordt gekeken naar het effect van zogenaamde
ACE-remmers op proteinurie, de snelheid van nierfunctieachteruitgang en de invloed
van de hoeveelheid zoutgebruik in het dieet. Tot slot wordt ook een onderzoek
beschreven waarbij we de hypothese van de toegenomen angiotensine-2 produktie
bij het DD genotype willen toetsen. Voordat de resultaten van ons onderzoek worden
besproken in hoofdstuk 3 tot en met 6,  volgt eerst  een literatuuroverzicht in
hoofdstuk 2.
Hoofdstuk 2
In hoofdstuk 2 bespreken we een groot aantal studies die over het ACE
polymorfisme zijn gepubliceerd. Eerst wordt besproken hoe de verdeling van de drie
genotypen onder de bevolking is. In een westerse bevolking heeft ongeveer 36% het
DD genotype, 48% het ID en 16% het II genotype. Het blijkt dat onder andere
bevolkingsgroepen de verdeling heel anders kan zijn. Zo komt het II genotype bij
Japanners juist het meest voor. Ook wordt besproken wat het ACE polymorfisme op
celniveau precies betekent. Het blijkt dat niet alleen in het bloed maar ook in
verschillende weefsels de ACE activiteit in relatie staat met het genotype. Het
variabele stukje insertie/deletie DNA van het ACE gen blijkt echter niet zelf de
informatie voor de produktie van het ACE te bevatten. Het kan dus nooit zelf het
verschil in de hoeveelheid ACE veroorzaken. Waarschijnlijk ligt het verantwoordelijke
stukje DNA vlak bij het insertie/deletie deel. Mogelijk zijn de bevindingen in de
literatuur bij verschillende rassen juist daarom zo anders omdat de relatie met dit nog
onbekende stuk DNA per ras kan verschillen. In de loop der jaren zijn de technieken
om het genotype bij de mens te bepalen verbeterd. Het insertiedeel is namelijk lastig
aan te tonen bij het ID genotype. Mensen met het ID genotype worden dan verkeerd
getypeerd als DD genotype. Met de nieuwe detectiemethoden bestaat dit probleem
niet meer. Vervolgens is in dit hoofdstuk veel aandacht besteed aan de rol van het
ACE polymorfisme in de nefrologie. Op dit moment zijn er nog weinig aanwijzingen
dat het DD genotype het risico op het krijgen van een bepaalde nierziekte vergroot,
met uitzondering van patiënten met suikerziekte (diabetes) waarvoor het DD
genotype mogelijk een groter risico geeft op diabetische nierschade. Er zijn
daarentegen veel aanwijzingen dat bij aanwezigheid van een nierziekte het DD
genotype een risicofactor is voor sneller nierfunctieverlies. Niet alle studies komen




meeste studies hebben gekeken of het DD genotype meer voorkomt in populaties
met een snellere achteruitgang van de nierfunktie. Deze onderzoeksmethode geeft
echter een aantal problemen waardoor de interpretatie van de studies en de
vergelijking met andere studies moeilijk is. Tussen deze studies verschillen de
eigenschappen van de patient nogal eens, zoals de soort nierziekte, de nierfunktie of
hun genetische afkomst. De mate waarin andere krachtige risicofactoren, zoals
bloeddruk en proteinurie, aanwezig zijn is waarschijnlijk van grotere invloed waardoor
in bepaalde patiëntengroepen de invloed van het ACE genotype moeilijk zichtbaar is
te maken. Tevens zijn de patiënten in de studies vaak niet goed in de tijd vervolgd
waardoor de definitie van snelheid van nierfunctieverlies wordt bemoeilijkt. Ook zijn
er allerlei andere factoren van belang bij het beloop van een ziekte en weet men
eigenlijk niet goed hoe het ACE-polymorfisme en bijvoorbeeld uitwendige factoren
zoals roken of zoutgebruik, elkaar precies beïnvloeden. Ten aanzien van de reactie op
behandeling met medicatie geldt eigenlijk hetzelfde verhaal. Door deze tegenstrijdige
resultaten is een aantal onderzoekers van mening dat de relatie tussen het DD
genotype en progressief nierfunctie verlies op puur toeval berust. Daarom is meer
basaal onderzoek van belang om te bestuderen wat de gevolgen zijn van het ACE
polymorfisme voor het functioneren van nieren en bloedvaten, zowel bij de gezonde
mens als bij patiënten met een nierziekte. Als deze mechanismen bekend zijn kan er
meer gericht onderzoek plaatsvinden. Alhoewel dit eigenlijk het belangrijkste soort
onderzoek is om de gevolgen van het ACE polymorfisme bij ziekten te kunnen
begrijpen, is hier in de literatuur maar weinig aandacht aan geschonken.  Een klein
aantal studies geeft argumenten voor de hypothese dat een hoger ACE bij mensen
met het DD genotype de vorming van  angiotensine-2 bevordert, maar andere
studies spreken dit tegen.  
Hoofdstuk 3
In dit hoofdstuk wordt ons onderzoek beschreven dat de invloed van het ACE
polymorfisme op de progressie van nierfunctieverlies bestudeert in relatie tot het
effect van therapie. In een eerdere studie van onze afdeling is onderzocht of het DD
genotype een invloed had op het beloop van de nierfunctie. Dit onderzoek vond
plaats bij patiënten met niet-diabetische nierziekten die werden behandeld met
medicijnen tegen hoge bloeddruk en proteinurie. Het bleek dat de nierfunctie bij
patiënten met het ID en II genotype vrij traag achteruitging gedurende de totale
onderzoeksduuur van 3 tot 4 jaar. De nierfunctie bij patiënten met het DD genotype
ging echter veel sneller achteruit. Dit ondanks het feit dat alle patiënten vergelijkbaar
waren ten aanzien van de verlaging in bloeddruk en proteinurie. De vraag was dus of
patiënten met het DD genotype minder baat hebben bij deze behandeling. Daarom
hebben we gekeken naar het nierfunctieverloop voordat de patiënten volgens het
onderzoeksprotocol werden  behandeld. Hieruit bleek allereerst dat de therapie
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volgens een vast protocol, met een tamelijk strenge streefwaarde voor bloeddruk,
een duidelijke verbetering liet zien in zowel bloeddruk als proteinurie in de
patiëntengroep als totaal. Ook voor de geprotocolleerde behandeling hadden
patiënten met DD genotype een nierfunctie die sneller achteruit ging in vergelijking
met patiënten met het ID en II genotype. Een opvallende bevinding was echter dat
het verschil in nierfunctieverlies voor en tijdens de optimale behandelingsfase bij de
ID en II patiënten relatief klein bleek. Bij DD patiënten was het verschil in
nierfunctieverlies voor en tijdens optimale therapie echter veel groter (dus een
grotere verbetering). Alhoewel naar aanleiding van ons eerdere onderzoek dus werd
gedacht dat de therapie bij DD patiënten minder effectief was, is behandeling dus wel
zinvol, al is deze onvoldoende effectief om het verlies van  nierfunctie even goed af
te remmen als bij het ID en II genotype. De resultaten lieten tevens zien dat het
effect van de behandeling bij patiënten met een snel achteruitgaande nierfunctie
relatief groot is, terwijl voor patiënten met een traag achteruitgaande nierfunctie het
effect relatief klein (maar toch niet onbelangrijk) is.
Hoofdstuk 4
Uit hoofdstuk 3 komt de vraag naar voren waarom patiënten met het DD
genotype op lange termijn slechter af zijn, ondanks het geven van therapie. Één van
de belangrijkste graadmeters voor succesvolle therapie op lange termijn is de mate
waarin de hoeveelheid proteinurie afneemt in de eerste 4 tot 12 weken van
behandeling met zogenaamde ACE-remmers. Dit zijn medicamenten die een
bloeddrukverlagend effect hebben maar ook de proteinurie kunnen verminderen. Een
slechte reactie in de eerste fase van behandeling voorspelt over het algemeen dat de
nierfunctie in de toekomst sneller achteruit gaat. In dit hoofdstuk wordt ons
onderzoek beschreven  waarbij is gekeken naar het korte termijn effect van ACE-
remmers in relatie met het ACE genotype. Dit is onderzocht bij 61 patiënten met
proteinurie. Uit het onderzoek bleek dat elk genotype even goed reageerde op ACE-
remmers. Zowel de bloeddruk, de nierdoorbloeding en de proteinurie verbeterde in
dezelfde mate. De conclusie lijkt dus dat de korte termijn reactie op ACE-remmers bij
patiënten met het DD genotype gelijk is aan het ID en II genotype. Of dit voor elke
patiëntenpopulatie geldt en onder alle omstandigheden, is echter niet zeker omdat in
sommige studies in de literatuur het ACE genotype soms wél bepalend lijkt voor het
effect op therapie. Waarschijnlijk heeft dit te maken met een verschil in de
patiënteneigenschappen of met verschillen in andere bijkomende factoren. Het is dus
niet uit te sluiten dat voor een andere specifieke categorie patiënten de reactie op
ACE-remmers wel afhankelijk is van het genotype. De invloed van deze specifieke
patiënteneigenschappen moet dan ook verder worden onderzocht. Ook kan het effect
van ACE-remmers op weefselniveau toch verschillen per genotype, maar dit is





In dit hoofdstuk wordt ons onderzoek beschreven waarbij we hebben
bestudeerd of de  hoeveelheid zout in het dieet het effect van een ACE-remmer bij
verschillende ACE genotypen beïnvloedt. Collega-onderzoekers uit Oostenrijk  vonden
in een vergelijkbaar onderzoek dat patiënten met proteinurie en het  DD genotype
juist slechter reageerden op ACE-remmers. Gezamelijk hebben we 88 patiënten met
proteinurie bestudeerd. In deze studie lag de nadruk op het effect van de
hoeveelheid zout in het dieet van de patiënten. De zoutinname is namelijk van belang
omdat ACE -remmers het meest effectief zijn bij een zoutbeperking in het dieet. Het
bleek dat de hoeveelheid zoutgebruik bij het II en ID genotype relatief weinig invloed
had op het effect van ACE-remmers ten aanzien van bloeddruk en proteinurie. Bij
patiënten met het DD genotype was het effect van ACE-remmers veel meer
afhankelijk van de hoeveelheid zout in het dieet. Bij veel zoutgebruik was de reactie
op de therapie slechter dan bij een goede zoutbeperking. Bij het interpreteren van
verschillende studies met andere patiëntenpopulaties dienen we dus rekening te
houden met verschillen in zoutgebruik. Een zoutbeperking als aanvulling op therapie
met ACE-remmers is dus mogelijk van meer belang bij patiënten met proteinurie en
het DD genotype.
Hoofdstuk 6
De gedachte dat het hogere ACE gehalte bij individuen met het DD genotype
leidt tot meer angiotensine-2 was tot nu toe slechts een hypothese. Hoofdstuk 6
beschrijft  ons onderzoek dat deze hypothese probeert te bewijzen. Bij gezonde
vrijwilligers werd angiotensine-1 toegediend en is gekeken naar het effect op de
bloeddruk, de nierdoorbloeding en de afgifte van belangrijke hormonen zoals
angiotensine-2 en aldosteron. Bij analyse bleek inderdaad dat bij het DD genotype
gedurende angiotensine-1 infusie de bloeddruk sterker steeg en dat de
vaatvernauwing in de nieren sterker toenam. Ook de afgifte van het hormoon
aldosteron was hoger dan bij het ID en II genotype. Dit zijn allemaal indirecte
aanwijzingen dat er meer angiotensine-2 is gevormd tijdens de infusie van
angiotensine-1. Jammer genoeg konden we geen hogere angiotensine-2 concentratie
in het bloed aantonen. Mogelijk is alleen de concentratie ter plekke van de weefsels
verhoogd. Andere onderzoekers vonden in vergelijkbare experimenten wel een hoger
angiotensine-2 in het bloed maar in deze studies werd meer angiotensine-1
toegediend.
De hoeveelheid zout in het dieet heeft op het RAAS een belangrijke invloed.
Weinig zoutgebruik activeert het RAAS, veel zoutgebruik onderdrukt het RAAS. Het
bovenstaande experiment is daarom ook tweemaal per vrijwilliger uitgevoerd.
Eénmaal na 1 week zoutbeperking (3 gram per dag, 6 boterhammen bevatten al 3
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gram zout!) en éénmaal na 1 week met veel zoutgebruik  (12 gram per dag, dit is
meer dan de gemiddelde Nederlander die ongeveer 9 gram per dag gebruikt). Uit de
analyse bleek dat het grotere effect van angiotensine-1 alleen maar kon worden
aangetoond na het hoge zoutgebruik. Een verklaring voor dit verschil is niet
eenvoudig te geven. Een hypothese kan zijn dat veel zoutgebruik bij het DD
genotype de ACE activiteit op weefselniveau sterk stimuleert of weinig zoutgebruik
ACE remt. Een andere mogelijkheid is dat hoog zoutgebruik  zorgt voor verminderde
afbraak van angiotensine-2, waardoor de grotere angiotensine-2 produktie een
sterker effect heeft. Voor deze hypothesen zijn nog geen bewijzen. De bevindingen
onderstrepen in ieder geval nogmaals dat erfelijke factoren een interactie kunnen
hebben met uitwendige factoren zoals bijvoorbeeld de hoeveelheid zout in het dieet.
CONCLUSIES
Het  ACE polymorfisme is het eerste genetische polymorfisme dat veel
aandacht heeft gekregen in de nefrologie. Het DD genotype is gerelateerd met een
hogere ACE activiteit in zowel bloed als weefsels. De mechanismen en gevolgen van
dit fenomeen zijn nog grotendeels onduidelijk. In het onderzoek beschreven in dit
proefschrift en in andere studies zijn zowel directe als indirecte bewijzen gevonden
dat een hogere ACE activiteit leidt tot meer angiotensine-2 produktie. Het aantal
studies is echter nog te gering om een definitieve conclusie te trekken, zeker omdat
niet alle studies dezelfde resultaten hadden. Op de diabetische nierschade na lijkt het
ACE genotype geen relatie te hebben met het ontstaan van nierziekten. Wel is een
ongunstig beloop aangetoond zoals in hoofdstuk 2. Dit geldt mogelijk niet voor alle
patiënten. Een aantal andere risicofactoren speelt hier ook een rol, omdat deze
waarschijnlijk een sterkere invloed hebben waardoor de verschillen tussen genotypes
moeilijker zichtbaar te maken zijn.  Patiënten met chronische nierziekten en het DD
genotype hebben wel degelijk baat bij therapie al is de uitkomst op lange termijn
uiteindelijk toch minder goed.  Een slechtere reactie op ACE-remmers op korte
termijn kon in ons onderzoek niet worden aangetoond. Patiënten met het DD
genotype die veel zout gebruiken zijn hierop mogelijk een uitzondering. Het effect op
weefselniveau is onbekend.  Op dit moment zijn er nog veel vragen onbeantwoord.
Daarom heeft het ACE polymorfisme op dit moment nog geen duidelijke waarde in de
klinische praktijk. Het onderzoek in dit proefschrift beschreven is slechts een begin
van een lange reeks vervolgonderzoeken naar de waarde van genetische
polymorfismen in de klinische praktijk. De resultaten van de hier gepresenteerde
studies zijn een stimulans voor de Afdeling Nefrologie van het Academisch Ziekenhuis
Groningen om het onderzoek naar de rol van het ACE polymorfisme, en andere nieuw
ontdekte polymorfismen  van het RAAS, te continueren. Het belangrijkste doel hierbij




behandeling behoeven ter preventie van progressief nierfunktieverlies. Het hebben
van een bepaald genotype is dan hopelijk niet alleen een risicofactor waar je niets
aan kunt doen, maar juist een aangrijpingspunt voor het instellen van een
effectievere vorm van therapie voor deze patiëntengroep.  




aldosteron hormoon geproduceerd door de
bijnierschors, afgifte wordt
gestimuleerd door angiotensine-2,
veroorzaakt vasthouden van water en
zout in de nier
angiotensine-1 stof van waaruit angiotensine-2
gemaakt wordt
angiotensine-2 belangrijk eindprodukt van RAAS,
veroorzaakt vaatvernauwing in onder
andere de nier, stimuleert afgifte van
aldosteron, speelt rol bij
weefselprocessen in de nier 
angiotensine-converting-enzym (ACE) stof die angiotensine-1 in
angiotensine-2 omzet
ACE-remmer een medicament wat het ACE remt.
Gebruikt als middel tegen hoge
bloeddruk en proteinurie, effectief
tegen progressief nierfunctieverlies
chronische nierinsufficiëntie een chronisch gestoorde nierfunctie,
met als belangrijk kenmerk het
geleidelijk aan achteruitgaan van de
nierfunctie
deletie het ontbreken van een stuk DNA in
een specifiek gen 
DNA molecuulstructuur die  alle erfelijke
informatie van het lichaam bij zich
draagt
genetisch polymorfisme erfelijke variatie op verschillende
genen, zonder direct aanleiding te




gen stuk DNA wat informatie bij zich
draagt van één eiwit
genotype één van de verschillende DNA
variaties op een gen met als gevolg
een genetisch polymorfisme wat
bestaat uit meerdere genotypen
insertie een extra stuk DNA in een specifiek 
gen
nefrologie vakgebied met betrekking op de leer
en de behandeling van nierziekten 
proteinurie eiwitverlies in de urine
renine-angiotensine-aldosteron complex van processen en stoffen
systeem (RAAS) met als uiteindelijk gevolg de
produktie van angiotensine-2 en de
stimulatie van aldosteron afgifte,
beide van groot belang bij de
regulatie van bloeddruk, nierfunctie
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Stellingen behorend bij het proefschrift
Angiotensin-converting enzyme gene I/D polymorphism and renal disease
1. Het ACE DD genotype is geassocieerd met sneller progressief nierfunctieverlies bij
patiënten met chronische nierinsufficiëntie. (dit proefschrift)
2. Door de vele associatiestudies naar het ACE I/D polymorfisme ontstaan zinloze
“welles-nietes” discussies. Het is nu tijd voor mechanistische studies met speciale
aandacht voor gen-omgevingsinteracties. (dit proefschrift)
3. De hoeveelheid zout in de voeding speelt bij patiënten met het DD genotype die
behandeld worden met een ACE-remmer mogelijk een grotere rol dan bij patiënten
met het ID en II genotype. (dit proefschrift)
4. Angiotensine I infusie veroorzaakt bij vrijwilligers met het DD genotype een groter
effect op bloeddruk, renale hemodynamiek en aldosteron afgifte dan bij het ID en II
genotype. Dit effect is alleen waarneembaar gedurende een hoog zout dieet. (dit
proefschrift)
5. Een relatief klein verschil in nierfunctieverlies per jaar tussen individuen kan
betekenen dat nierfunctievervangende therapie pas vele jaren later geïndiceerd is.
Een relatief milde risicofactor zoals het ACE DD genotype kan dus wel degelijk
klinische consequenties hebben. (dit proefschrift)
6. Humor en gezelligheid op de werkplek zijn de belangrijkste wapens tegen burnout
7. In de media wordt de term “medische fout” vaak misbruikt of verward met de term
“medische complicatie”. 
8. Tien jaar lang goed doen is niet goed genoeg, één dag kwaad doen is teveel. (Chinese
wijsheid) 
9. Hoe vaker je een manuscript verandert, hoe meer het gaat lijken op de eerste versie.
10. De Australische kreet “no worries“ is niet van toepassing op het schrijven van een
proefschrift.
11. Als je haast hebt ga dan zitten.
Frank van der Kleij
Groningen, 13 november 2002
